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ABSTRACT 
The peptide, apelin, is expressed in fat cells, endothelial cells, and CNS neurons. Increasing 
evidence (e.g. inotropic and vasomotor effects) supports a role for apelin in the regulation of the 
cardiovascular system. This research aimed to understand vascular effects of apelin and bridge 
gaps in the knowledge about apelin-induced effects on different vascular beds i.e. cerebral and 
coronary arteries. My first objective was to assess apelin-induced vascular effects in cerebral 
arteries. Based on current data, one could conclude that apelin by itself has no effects on vasomotor 
tone of cerebral arteries, but it does impair nitric oxide dependent relaxations of cerebral arteries, 
possibly by inhibiting functions of large conductance calcium activated potassium (BKCa) 
channels. 
Apelin increases coronary blood flow; however, the involved mechanism(s) has not yet 
been elucidated. Hence, my next aim was to determine the mechanism(s) involved in apelin-
induced vascular effects. The results suggest that apelin causes endothelium APJ receptor 
dependent relaxation of coronary arteries, which is possibly mediated by nitric oxide dependent 
direct activation of BKCa channels. Interestingly, my results also suggest that pathways involved 
in apelin-induced coronary arteries relaxation are markedly different from another endothelium 
dependent vasodilator, acetylcholine. This research is the first to report that nitric oxide, generated 
in response to different stimuli, can likely activate more than one signaling pathways in coronary 
arteries.  
In my final aim, I determined effects of apelin on smooth muscle BKCa channel functions 
in coronary arteries.  My data suggest that functionally active apelin-APJ signaling has no 
inhibitory effects on BKCa channel functions and does not inhibit nitric oxide-induced relaxations 
of coronary arteries. Possible reasons for difference in apelin response between cerebral and 
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coronary arteries could be associated with differences in activation of G-proteins and PI3K 
signaling pathways between these two vascular beds. 
Altogether, this research provides an improved understanding about apelin-induced 
vascular effects in cerebral and coronary arteries, and highlights some key mechanistic differences 
in apelin-induced vascular effects between these two blood vessels. Moreover, this knowledge 
may have important therapeutic implications in future design and development of apelin analogs 
for treatment of cardiovascular diseases. 
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CHAPTER 1. INTRODUCTION 
Cardiovascular diseases are leading cause of death with ~17.3 million deaths per year; 
predicated to reach ~23.6 million by 2030 (1). Cardiovascular diseases are complex multifactorial 
disorders and underlying pathology varies from inflammation, endothelial dysfunction to blood 
vessels damage. There is steady decrease in clinical trials for cardiovascular diseases in past two 
decades and new interventions are only providing small benefits over existing molecules (2). The 
disease burden is major cause of concern and calls for better therapeutic strategies. Apelin is 
considered as one of the novel therapeutic target in cardiovascular research due to its protective 
actions (3). 
APJ signaling is modulated in many diseases including cardiovascular, HIV, 
neurodegenerative and metabolic to name a few. From the time of discovery, enormous 
information is gathered about APJ signaling and their modulation during cardiovascular diseases. 
Scientists have identified many novel and characteristic details about APJ signaling that involves 
diverse intracellular mechanism(s). Apelin and APJ receptor are ubiquitously expressed in 
mammalian central and peripheral system (4, 5). This expression pattern along with multiple roles 
in physiology has continuously attracting the scientific community for evaluating potential roles 
of apelinergic system in cardiovascular diseases (3, 6). Currently, several on-going clinical trials 
are evaluating vascular effects of apelin in health and disease states. Besides, growing body of 
knowledge is bringing several new updates about apelinergic system, including new ligands 
(Apela/ELABELA/Toddler) (7, 8), synthesis analogs (E339-3D6, ML-233) (9, 10) and antagonist 
(F13A, ML221) (11, 12). Many reports are now showing previously unidentified or novel 
mechanistic role(s) of apelinergic system (13, 14). From the time of discovery, researchers are 
focused to identify apelin-induced vascular effects. Until now, many intracellular mediators i.e. 
 2 
 
endothelial nitric oxide synthase (eNOS), phosphoinositol-3 kinase (PI3K), protein kinase C 
(PKC) and many others are shown to be involved in vascular effects of apelin. However, we still 
lack a comprehensive understanding about regulatory role of apelin on vasomotor tone.  
Apelin and Other Analogs 
Discovered in 1998, apelin was initially considered as a sole endogenous ligand for APJ 
receptor (15), until the recent discovery of another peptide, apela/Toddler/Elabela (7, 8). Apelin 
gene is located on band q25-26.1 of the chromosome X and is highly expressed in lungs, mammary 
gland, heart and vascular endothelial cells (16-18). Apelin-77 (Pre-pro-apelin) is the precursor of 
various pharmacological active apelin isoforms (apelin-12, -13, -17 and -36), and shares a 75-95% 
sequence homology among various species including rat, mice and bovine (19). N-terminal 
residues of apelin-77 are post-transnationally modified by endopeptidase to form pro-apelin-55, 
which is further cleaved to apelin-36, -17, -13 and -12 (Figure 1). All these fragments have a 
conserved C-terminal region, which is essential for APJ receptor binding and functional activity 
(20). Additionally, post-translationally modification of N-terminal residue of apelin-13 with a 
cyclized glutamine forms [Pyr]-apelin-13 that evades enzymatic degradation and results into a 
longer biological effects (21). These different apelin isoforms (apelin-12, -13, -17 and -36) have 
variable potency, but apelin-13 and [Pyr]-apelin-13 are identified as more predominate and potent 
isoforms in cardiovascular system (15, 22). Based on the essential role of C-terminal, Lee et al. 
has designed a functional antagonist; F13A by synthetic replacement of C-terminal phenylalanine 
residue with alanine, which inhibited apelin induced hypotensive effects (11). 
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Fig. 1. Schematic representation for synthesis of apelin. 
 
Although apelin has potent vascular effects, but its shorter biological life (19), and lack of 
complete information about its degradation pathways makes design and development of synthetic 
apelin analogs a challenging process. A few studies have shown role of angiotensin converting 
enzyme type-2 (ACE-2), a zinc-containing carboxy monopeptidase is partially responsible for the 
metabolism of apelin (23-25). Wang et al. showed that [Pyr]-apelin-13 is more susceptible towards 
ACE-2 degradation than apelin-17, and resulted metabolites i.e. [Pyr]-apelin-12 and apelin-16 
respectively have reduced functional activity (23). Another recent report showed that ACE-2 
metabolizes [Pyr]-apelin-13 to biologically active [Pyr]-apelin-13 (1-12), suggesting beneficial 
effect of increased ACE-2 expression during cardiovascular diseases (24). Researchers are 
continuously trying to develop biologically stable analogs of apelin (26, 27), and information 
related to metabolism and degradation can further support the development.  
APJ Receptor 
APJ receptor is a G-protein coupled receptor (GPCR) located in chromosome 11 and 
composed of an intron-less (APLNR) gene, which is conserved in many species including human, 
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monkey, chimpanzee, mice and rat (20). APJ receptor was first discovered by O’Dowd et al. in 
1993 during their search for vasopressin receptor (28). APJ receptor has a 380 amino acid sequence 
with G-protein characteristic including seven transmembrane domains and post-translation 
modification sites for phosphorylation, palmitoylation and glycosylation along with association 
site for β-arrestin (28). Moreover, APJ receptor shares ~34% sequence homology with AT-1 
receptor, but does not have binding affinity for angiotensin II (28). 
APJ receptors are associate with heterotrimeric G-protein and multiple G-subunits are 
associated with apelin-induced effects. Initial work suggested involvement of pertussis toxin 
sensitive Gαi/o subunits that inhibits forskolin induced cAMP formation in CHO cells (15). These 
findings were later strengthened by apelin-induced inhibition of intracellular Ca2+ mobilization in 
CHO cell lines expressing APJ receptor (29). We have also shown that apelin-inhibits BKCa 
channel currents in cerebral vascular smooth muscle cells via pertussis toxin sensitive Gαi/o-subunit 
(30). However, apelin was also found to increase Ca2+ mobilization in neuronal cells (31), 
indicating involvement of other G-subunits.  In subsequent research, apelin induced cardiac and 
smooth muscle contractile response were attenuated by phospholipase C and protein kinase C 
inhibitors, adding Gαq/11 subunit to APJ receptor (32, 33). In addition to these two subunits, 
functional role of Gα13 subunit has been deciphered in apelin-induced cytoplasmic translocation of 
histone deacetylase during cardiac and vascular development (34).  
Central and peripheral expression of APJ receptor makes it an attractive target for 
cardiovascular regulation (16). Similarly, both membranous and nuclear expression of APJ 
receptor in hypothalamus and blood vessels indicates involvement of apelinergic system in signal 
transduction and gene regulation (35). Moreover, central versus peripheral administered apelin is 
shown to have different effects of hemodynamics and energy metabolism (36, 37). These previous 
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studies were focused on neurohormonal effects of apelin, but it is essential to understand vascular 
effects of central and peripheral administered apelin.  
Vascular Effects of Apelin 
Apelin has complex vasomotor effects as it can cause either vasodilation or 
vasoconstriction depending on the vascular bed and underlying conditions. These dual actions are 
attributed to the presence of APJ receptor on endothelial and smooth muscle cell layers of blood 
vessels. The following sections summarizes the current available information about vasoactive 
effects of apelin.  
Role of Apelinergic System in Vasodilation 
Apelin has multiple mechanisms to control vascular tone, possibly involving nitric oxide 
and prostanoids (22, 38). Interestingly, apelin can reduce both pre- and after-load due to its arterial 
and venodilation abilities (39). Researchers are continuously reporting role of nitric oxide in 
vascular effects of apelin (3, 40-43), however majority of these experiments were done using 
indirect approach i.e. with eNOS inhibitors, which cannot specifically differentiate between NO 
and other reactive nitrogen species (44, 45). Further, the downstream signaling mechanism(s) 
activated in response to apelin and nitric oxide signaling have not studied thus far.  Intracellular 
nitric oxide can relax vascular smooth muscle cells by various mechanisms including well 
established cGMP dependent pathways (46, 47) or by other mechanisms like direct activation of 
BKCa channels (48, 49), activation of SERCA pump (50) and by inhibiting effects of 
vasoconstrictive mediators i.e. 20-HETE (51).  Major body of current knowledge focuses on role 
of nitric oxide in apelin-induced vasodilation and hypotensive effects (18, 40, 41, 43, 52), but 
further studies are required to determine downstream mediators activated in response to apelin-
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induced nitric oxide and this knowledge will possibly provide a paradigm-shift in apelinergic 
signaling cascade.  
Not only the mediators, but apelin-induced hypotensive effects are also under critical 
scrutiny. Charles et. al observed a biphasic hemodynamic response with bolus apelin treatment in 
conscious sheep, where transient fall in arterial pressure was followed by a rise in arterial pressure 
(53). Likewise, in conscious rats, peripheral administration of apelin failed to produce a depressor 
response, but caused a pressor response (54). These reports suggest that apelin-induced response 
is mediated by complex intracellular events involving multiple mediator(s), which may not be 
dissected using isolated preparations and demands for a better correlation using in-vitro and in-
vivo studies. Moreover, various apelin isoforms are also shown to have different potency in 
different experimental models. For example, Tatemato et al. reported that apelin-12 is more potent 
in reducing mean arterial pressure (MAP) in comparison to apelin-13 and -36 in anesthetized 
normotensive rats (55).  However, apelin-17 is shown to cause higher depressor response as 
compared to [Pyr]-apelin-13 and apelin-15 in normotensive rats (56).  Whereas, Lee et al. 
suggested that apelin-13 has higher potency in comparison to apelin-12 using spontaneous 
hypertensive rats (11). These differences can also be attributed to differences in apelin response 
between central and peripheral systems (54, 57).  
Cardiovascular regulatory regions of brain controls the peripheral vascular resistance and 
tone, and apelinergic system is highly expressed in cardiovascular regulatory regions i.e. 
hypothalamus and brain stem (58). Moreover, apelin induced central response is suggested to be 
different from peripheral vasodilation (59, 60). Our previous report also suggests that apelin 
inhibits BKCa channels currents in cerebral arterial smooth muscle cells (30). Potassium channels 
including BKCa channels are highly expressed on cerebral arteries and are responsible for 
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maintaining membrane potential (61). Functional inhibition of BKCa channels can alter vascular 
tone; resulting into vasospasm and ischemia (62). These findings raised questions about 
differences in vasoactive response mediated by apelin in cerebral and peripheral system.  
Role of Apelinergic System in Vasoconstriction 
Vasoconstriction is known to be regulated by calcium release (63), myosin like chain 
(MLC) phosphorylation (64) and ion channels (65). Hashimoto et al. showed that apelin causes 
vasoconstriction in mice thoracic aorta by increasing phosphorylation of MLC via Gαi/o dependent 
activation of PKC and Na+-Ca2+ exchanger dependent pathways (33). Moreover, apelin is shown 
to permeate through dysfunctional endothelial cells (66), to cause vasoconstriction by 
phosphorylation of MLC (67). Likewise, Maguire et al. also reported [Pyr]-Apelin-13 induced 
vasocontractile response in human endothelial denuded saphenous vein and mammary arteries 
(22). Interestingly, most of smooth muscle dependent effects of apelin are derived either from 
endothelial denuded or dysfunctional blood vessels or from in-vitro cell culture studies. 
Nevertheless, we need answers for biphasic hemodynamic changes observed during in-vivo 
conditions (53), which requires an advanced technical approach to characterize these changes at 
the level of endothelial as well as smooth muscle cell individually. 
Regulation of apelin-APJ receptor during endothelial dysfunction and cardiovascular 
disease remains controversial. On one hand, increased apelin/APJ receptor expression and 
bioavailability produced beneficial vascular effects in the conditions with endothelial dysfunction 
like end-stage heart failure (68), atherosclerosis (69) and obesity (41), while others have also 
shown apelinergic signaling can be a mediator for atherosclerosis (70), indeed up-regulated apelin 
gene is localized in atherosclerosis plaques (18) and stenotic aortic valve (71).  It is important to 
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know that whether this increased expression of apelin has a role in progression of disease or is 
involved in compensatory feedback mechanism (69). 
Higher expression of both apelin and APJ receptor on cardiovascular regulatory regions of 
brain (58), suggest involvement of apelin signaling in hemodynamic regulation. Previous studies 
showed site specific delivery of apelin to brain stem regions i.e. nucleus tractus solitarius (NTS) 
and rostral ventrolateral medulla (RVLM) caused a sustained increase in arterial pressure (57), 
possibly by mitogen activated protein kinase dependent pathway (72). Similarly, our previous 
reports suggested apelin microinjection into RVLM elevates blood pressure and sympathetic nerve 
activity, via NAPDH oxidase derived superoxide(s) (59, 60). Moreover, we showed that 
upregulation of apelin gene in normotensive rats can cause chronic increase in blood pressure, 
similar to hypertensive rats (59). Similarly, intracerebroventricular injection of [Pyr]-apelin-13 
increased mean arterial pressure and heart rate by increasing c-fos expression in paraventricular 
nucleus (PVN) region of hypothalamus (54). Most of these studies were focused on estimating 
neurohormonal mechanism(s) involved in regulation of peripheral resistance and vascular tone, 
but involvement of apelin in cerebral vascular tone and blood flow still needs evaluation.   
Research Gaps 
Apelin is an endogenous peptide, which activates APJ receptor. Apelin is involved in 
cardiovascular homeostasis due to its vasodilation and positive inotropic actions (73). However, 
apelin-induced vasoactive effects are determined in very limited blood vessels, which do not 
include cerebral and coronary arteries.  Apelin is synthesized in vascular endothelial cells and 
adipose tissues (4), and found to mediate autocrine and paracrine effects on vasculature (74). It 
has been reported that apelin induces hypotensive effects (19) by activating APJ receptor (75) and 
through nitric oxide dependent pathways (43, 55). Moreover, apelin causes vasoconstriction in 
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endothelium denuded/dysfunctional blood vessels (66, 67).  Previous data suggested that apelin 
inhibits BKCa channel currents in cerebral arteries smooth muscle cells (30). Nonetheless, whether 
this inhibition of BKCa channels has negative impact on nitric oxide dependent relaxation and in 
turn on vasomotor tone has yet to be determined. It is also important to note that apelin is shown 
to increase forearm blood flow (52, 76) and can cause vasodilation in peripheral arteries (22). 
However, mediators and pathways involved in apelin-induced relaxation of coronary arteries have 
not been studied thus far. Apelin and its analogs are currently under clinical trials, evaluating their 
therapeutic benefits in pulmonary hypertension and myocardial infraction 
(https://clinicaltrials.gov/). Considering its enormous therapeutic potential, it is timely to evaluate 
apelin-induced vasoactive response in cerebral and coronary arteries. 
The central hypothesis of this research is that activation of apelin-APJ axis inhibits 
nitric oxide-induced relaxations in cerebral arteries by inhibiting BKCa channel functions. 
Further, apelin relaxes coronary arteries by nitric oxide dependent activation of smooth 
muscle BKCa channels. The proposed research will significantly reduce critical gaps in the 
knowledge about apelin-induced effects on cerebral and coronary arteries. 
I set the following specific aims to test my central underlying hypothesis and accomplish 
the overall objective of this research.  
Specific Aim 1: Determine vascular effects of apelin on nitric oxide dependent 
relaxation of cerebral arteries. Previous data demonstrated that apelin inhibits BKCa channel 
currents in cerebral arteries (30).  BKCa channels are key mediators for maintaining membrane 
potential and are involved in endothelium nitric oxide dependent relaxation. Hence, the aim is to 
evaluate effects of apelin on nitric oxide-induced relaxation of cerebral arteries. 
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Specific Aim 2: Determine vascular effects of apelin in coronary arteries. Previous 
studies demonstrated that apelin increases coronary blood flow and has beneficial effects during 
heart failure (42, 52). In a few peripheral arteries, apelin is shown to induce nitric oxide dependent 
vasodilation (22). However, effects of apelin on coronary arterial vasoactive tone has not been 
evaluated thus far. Therefore, the present aim is to evaluate effects of apelin on coronary arterial 
vasomotor tone and understand involved downstream signaling mechanisms. 
Specific Aim 3: Determine effects of apelin on BKCa channel functions in coronary 
arteries and compare the similarities/differences in signaling mechanisms with cerebral 
arteries. Apelin is shown to cause vasoconstriction in endothelium denuded or dysfunctional 
blood vessels (33, 67). Vasoconstriction can be regulated by protein or ion channels. Thus, the 
present aim is to determine effects of apelin on BKCa channel currents and functions in coronary 
arteries. Further, I aim to compare possible signaling events activated in response to apelin in 
coronary arterial smooth muscle cells, with cerebral arteries. 
This research has a marked impact on current and on-going clinical trials, and drug 
development process. This research provides a comprehensive understanding about vasoactive 
role(s) of apelin in cerebral (central) and coronary (peripheral) arteries, which will help in devising 
apelin-based therapies with higher beneficial effects and lesser-associated risks. It is essential to 
understand the risks associated with conditions with higher plasma apelin levels like diabetes and 
obesity, before bringing apelin from bench-to-bedside. Apelin has multifaceted roles in diabetes, 
cancer, and neurodegenerative disorders; therefore, this research will have broader implications, 
by enhancing our understanding about the apelinergic system in health and disease.  
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CHAPTER 2. APELIN IMPAIRS NITRIC OXIDE-INDUCED 
RELAXATION OF CEREBRAL ARTERIES BY INHIBITING 
ACTIVATION OF LARGE CONDUCTANCE, CALCIUM-ACTIVATED K 
CHANNELS 
Introduction 
Apelin is an endogenous peptide that is emerging as an important signaling molecule in 
several organ systems, including the cardiovascular system (77). Apelin binds to a single G-
protein-coupled receptor, termed APJ, which is widely expressed in peripheral organs and tissues 
as well as the central nervous system (28, 78). With respect to the cardiovascular system, APJ 
receptors are found in heart (5, 79), blood vessels (5, 18), and cardiovascular regulatory centers in 
the brain (58, 78, 80). 
A growing body of evidence supports a role for the apelin/APJ receptor signaling system 
in the regulation of blood vessel diameter. Studies indicate that apelin is a powerful vasodilator 
with an efficacy that exceeds that of hydralazine or nitrates (39, 42). This action, along with its 
inotropic effects on the heart, has led to the proposition that modulating the apelin/APJ system 
may offer a novel and rational therapeutic strategy for treating certain cardiovascular disorders, 
including myocardial ischemia, pulmonary arterial hypertension, and heart failure (42, 81). 
A confounding factor, however, is that the effect of APJ receptor activation on vascular 
tone is dependent on the particular vascular bed being studied. While APJ receptor stimulation 
leads to endothelium- and NO-dependent vasodilation in several blood vessels (22, 38), it can also 
result in vascular smooth muscle contraction in others (22, 67). These divergent vasomotor effects 
of apelin are consistent with the widely recognized heterogeneity that exists among blood vessels 
from different origins in terms of their reactivity to vasoactive agents (82). Therefore, whereas 
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systemic administration of apelin may have an overall beneficial hypotensive effect, it could also 
result in dangerous vasoconstriction in specific vascular beds. 
Our knowledge of the vasomotor actions of apelin in specific blood vessels is rather limited 
at the present time. One important vascular bed that has not been rigorously investigated with 
respect to the apelin/APJ system is the cerebral vasculature; however, a potential vasoconstrictor 
role for apelin in the regulation of cerebral arterial tone is suggested by our recent finding that 
apelin inhibits large conductance, calcium-activated K (BKCa) channel currents evoked by voltage-
dependent increases in membrane potential in cerebral artery smooth muscle cells (30). Thus, in 
cerebral arteries the net effect of apelin on blood vessel diameter could be the result of the ability 
of APJ receptor activation on the endothelium to evoke NO-dependent relaxations on one hand 
versus the effect of APJ receptor activation on the smooth muscle to inhibit relaxation via 
interference with NO-induced increases in BKCa currents. In the present study, I assessed the 
question of the net effect of apelin in cerebral arteries, as well as the hypothesis that the actions of 
apelin in cerebral arteries are indeed secondary to stimulation of APJ receptors. 
Material and Methods 
Animals and Tissue Preparation: Experiments were performed on tissues isolated from 
12-week-old male Sprague-Dawley rats (Envigo RMS, Indianapolis, IN). Rats were housed at 22 
± 2°C on a 12 h-12 h light-dark cycle and provided with food and water ad libitum. All animal 
protocols were approved by the North Dakota State University Institutional Animal Care and Use 
Committee. Brains were isolated from animals anesthetized with isoflurane and placed into ice-
cold physiological salt solution (PSS) with the following composition (in mM): NaCl 119mM, 
NaHCO3 15mM, KCl 4.6mM, MgCl2 1.2mM, NaH2PO4 1.2mM, CaCl2 1.5mM and glucose 
5.5mM.  Middle cerebral arteries were dissected and cleaned of surrounding tissue.  
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Western Immunoblotting: After collection, cerebral arteries were immediately frozen in 
liquid nitrogen. Tissues were homogenized in lysis buffer and supplemented with a protease and 
phosphatase inhibitor cocktail (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 4°C using an 
IKA Ultra-Turrax T8 homogenizer (IKA Works Inc., Wilmington, NC). Tissue homogenates were 
kept on ice for 10 min and then centrifuged at 10000g for 10 min.  Supernatant was collected and 
protein determination was performed using a Pierce BCA protein estimation kit (ThermoFisher 
Scientific, Waltham, MA). Aliquots of supernatant containing equal amounts of protein (40 μg) 
were separated on 7.5-10% polyacrylamide gel by SDS-polyacrylamide gel electrophoresis, and 
proteins were electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, 
Hercules, CA). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS, pH 7.4) 
and incubated overnight at 4°C with a primary antibody specific for APJ receptors using a dilution 
of (1:200) (Santa Cruz Biotechnology Inc.). Membranes were washed three times for 10 min using 
TBS-Tween 20 and incubated with a horseradish peroxidase-linked secondary antibody (Santa 
Cruz Biotechnology Inc.).  To ensure equal loading, the blots were analyzed for β-actin expression 
using an anti-actin antibody (Santa Cruz Biotechnology Inc.).  Immuno-detection was performed 
using an enhanced chemiluminescence light detection kit (ThermoFisher Scientific). 
RT- qPCR: Freshly isolated arteries were immediately frozen in liquid nitrogen and total 
RNA was isolated using an RNeasy Mini kit according to the manufacturer’s protocol (Qiagen, 
Germantown, MD). The concentration and purity of RNA was determined using a 
spectrophotometer (Nanodrop Technologies, Wilmington, DE).  cDNA was synthesized using 50 
ng of RNA and an iScript cDNA synthesis kit (Bio-Rad).  A Sybr Green expression assay was 
used to determine expression of APJ receptors, with β-actin used as a housekeeping gene (Bio-
Rad). The following primers (synthesized by Invitrogen, Carlsbad, CA) were used:  
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APJ receptor – forward: 5’-ACAAGACATGTGCCATTGGA-3’; reverse: 5’-
TCTCCCAGAAGCCTCCTACA-3’; β-actin – forward: 5’-GTCGTACCACTGGCATTGTG-3’; 
reverse: 5’-TCTCAGCTGTGGTGGTGAAG-3’.  Real-time RT-PCR reaction conditions were 
95°C for 10 min, followed by 40 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 30 s. 
Immunofluorescence Microscopy: Freshly isolated cerebral arteries were fixed in 10% 
formalin solution, processed and embedded in paraffin blocks. Paraffin blocks were sectioned at 5 
μm and mounted onto ProbeOn Plus microscopic slides (ThermoFisher Scientific). Sections were 
fixed by heating at 60°C for 30 min. Nonspecific antibody binding was blocked with normal serum 
[10% w/v; in TBS] for 1 h at room temperature. Sections were incubated overnight at 4°C in 1% 
serum containing a primary antibody against APJ receptors (Abcam, Cambridge, MA) and/or 
smooth muscle actin (Santa Cruz Biotechnology) or isotype control (Abcam). For co-localization 
of APJ receptor with smooth muscle actin, double immunofluorescent staining was performed by 
incubating the tissue sections with more than one primary antibody at the same time. Detection of 
the primary antibodies against the APJ receptor and smooth muscle actin was accomplished using 
Texas red-conjugated (goat anti-rabbit IgG; Invitrogen, Carlsbad, CA) and Alexa Fluor-488 (goat 
anti-mouse IgG; Santa Cruz Biotechnology) secondary antibodies, respectively. Rat lung tissue 
was used as positive control for APJ receptor detection (58). All negative controls were incubated 
overnight at 4°C with either 1% serum and/or an isotype control antibody for APJ receptors, 
followed by secondary antibodies. All dilutions and thorough washes between stages were 
performed using TBS containing Triton X-100 [0.3% (v/v)] unless otherwise stated.  Sections were 
drained by blotting with filter paper, and a drop of mounting medium containing an anti-fade 
reagent (Vector Laboratories, Burlingame, CA) was added to the slides.  Images of the sections 
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were obtained using an Olympus confocal laser-scanning microscope (Olympus, Tokyo, Japan).  
The images were generated using Olympus FluoView FV300 (v. 4.3) confocal software. 
Vascular Function Studies: Arterial rings (80-100 µm; 1.2 mm in length) were suspended 
in wire myographs (DMT, Aarhus, Denmark) for isometric tension recording. The myograph 
chambers were filled with PSS (5 ml), which was continuously aerated with 95% O2/5% CO2 and 
maintained at 37°C throughout the experiment. The vessel rings were stretched to an initial tension 
of 1.2 mN and allowed to stabilize for 7 minutes, followed by another stretch to 2.4 mN with 
stabilization for 7 minutes. At end of stretching, vessels were allowed to equilibrate for 30-40 min 
with intermittent washings. Vessel reactivity was confirmed by evoking a response to KCl (60 
mM) (83). In some vessels, the endothelium was removed by gently rubbing the intimal surface 
with a human hair. The presence or absence of endothelium was confirmed by measuring 
relaxation in response to the endothelium-dependent vasodilator, bradykinin (10-7 M).  Responses 
to the vasodilators used in this study were obtained in arterial rings contracted with 5-HT (10-7 M). 
Inhibitors were added to the myograph chamber 20 min prior to contraction with 5-HT, with the 
exception of apelin (10-7 M), which was added 5 min after the contraction had stabilized in order 
to minimize desensitization of APJ receptors. This concentration of apelin was selected because 
in previous studies it produced the greatest inhibitory effect on BKCa channel currents in rat 
cerebral smooth muscle cells (30). After addition to the myograph chamber, the inhibitors 
remained in contact with the tissues for the remainder of the experiment. Experiments with 
inhibitors were conducted in parallel with untreated control rings taken from the same animal. 
Cerebral Artery Smooth Muscle Cell Isolation: Enzymatic isolation of single vascular 
smooth muscle cells was carried out as described previously, with brief modification (84). Arteries 
were placed in cell isolation solution of the following composition (in mM): 60 NaCl, 80 Na-
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glutamate, 5 KCl, 2 MgCl2, 10 glucose, and 10 HEPES (pH 7.2). Arterial segments were initially 
incubated in 1.2 mg/ml papain (Worthington) and 2.0 mg/ml dithioerythritol (Sigma Aldrich) for 
17 min at 37°C and then in 0.8 mg/ml type II collagenase (Worthington) for 12 min at 37°C. The 
digested segments were washed three times in ice-cold cell isolation solution and incubated on ice 
for 30 min. After this incubation period, vessels were triturated to liberate smooth muscle cells and 
stored in ice-cold cell isolation solution for use. Smooth muscle cells were studied within 6 h 
following isolation. 
Electrophysiological Recording: Isolated smooth muscle cells were placed into a 
recording chamber (Warner Instruments, Hamden, CT) and allowed to adhere for 20 min at room 
temperature. Whole cell currents were recorded using an AxoPatch 200B amplifier equipped with 
an Axon CV 203BU headstage (Molecular Devices). Current data were collected and analyzed 
with pCLAMP 10.0 software (Molecular Devices, Sunnywale, CA). The patch electrodes (3-4 
MΩ) were fabricated from 1.5-mm borosilicate glass capillaries. Smooth muscle cells were 
superfused at a rate of 2.0 ml/min with a solution containing (in mM) 145 NaCl, 5.4 KCl, 1.8 
CaCl2, 1 MgCl2, 5 HEPES, 10 glucose; pH 7.4 (NaOH). Patch pipettes were filled with internal 
pipette solution containing (in mM) 145 KCl, 5 NaCl, 0.37 CaCl2, 2 MgCl2, 10 HEPES, 1 EGTA, 
7.5 Glucose; pH 7.2 (KOH). All drugs were diluted in fresh bath solution and perfused into the 
experimental chamber. Voltage-activated currents were filtered at 2 kHz and digitized at 10 kHz, 
and capacitative and leakage currents were subtracted digitally. Series resistance and total cell 
capacitance were calculated from uncompensated capacitive transients in response to 10 ms 
hyperpolarizing step pulses (5 mV), or obtained by adjusting series resistance and whole-cell 
capacitance using the Axopatch 200B amplifier control system. Standard recording conditions for 
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BKCa currents were achieved by stepping in 10 mV increments from a holding potential of -60 to 
+80 mV. BKCa currents were expressed as current density (current divided by its capacitance). 
Cyclic GMP Estimation: A competitive ELISA method was used to measure cyclic GMP 
levels in cerebral arteries. Arterial segments were equilibrated in PSS for at least 20 min at 37°C. 
After the equilibration period, arterial segments were treated with bradykinin (10-7 M, 5 min) or 
DEA NONOate (DEA; 10-6 M, 5 min). In some experiments, arterial segments were pretreated 
with apelin (10-7 M) for 5 min, before being exposed to bradykinin or DEA NONOate. After drug 
treatments, segments were immediately frozen in liquid nitrogen and homogenized with an IKA 
Ultra, Turrax-T8 homogenizer (IKA Works) at 4°C in 0.1 M hydrochloric acid. Tissue 
homogenates were centrifuged for 10 min at ≥600 g. Cyclic GMP and total protein content were 
determined in the supernatant as described in the direct cyclic GMP enzyme immunoassay kit 
(Assay Design, Ann Arbor, MI) and Pierce BCA protein assay kit (ThermoFisher Scientific), 
respectively. Cyclic GMP levels were expressed as picomoles per microgram of protein. 
Drugs: The following drugs were used: bradykinin, diethylamine NONOate (DEA 
NONOate), diltiazem, 5-hydroxytryptamine (5-HT), indomethacin, levcromakalim, NS1619, and 
nitro-l-arginine (NLA) (Sigma Chemical, St. Louis, MO); BMS 191011, iberiotoxin, and 
1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (Tocris, Ellisville, MO); apelin-13, and 
F13A (H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH trifluoroacetate salt) 
(Bachem, Torrance, CA). Drug solutions were prepared fresh daily, kept on ice, and protected 
from light until used. All drugs were dissolved in double-distilled water with the exception of 
ODQ, BMS 191011, and NS1619, which were dissolved initially in DMSO, and indomethacin, 
which was dissolved initially in 1 mM sodium carbonate, prior to further dilution in double-
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distilled water. Drugs were added to the myograph chambers in volumes not greater than 0.02 ml. 
Drug concentrations are reported as final molar concentrations in the myograph chamber.  
Data Analysis: Relaxation responses are expressed as a percent of the initial tension 
induced by 5-HT (10-7 M). EC50 values (drug concentration that produced 50% of its own maximal 
response) were determined, converted to their negative logarithm, and expressed as -log molar 
EC50 (pD2). RT-qPCR data were analyzed to quantify relative gene expression by ΔCt relative to 
β-actin. Results are expressed as means ± SEM, and n refers to the number of animals from which 
blood vessels were taken, unless otherwise stated. Values were compared by Student’s t-test or 
one-way ANOVA using Tukey’s test as post-hoc analysis for paired or unpaired observations, as 
appropriate, to determine significance between groups. Values were considered significantly 
different when p<0.05. 
Results 
APJ Receptor Expression in Cerebral Arteries 
RT-qPCR and immunoblot analyses were used to evaluate APJ receptor mRNA and protein 
expression, respectively. Figure 2 shows that APJ receptor protein (Figure 2A) and mRNA 
transcripts (Figure 2B) are expressed in cerebral arteries; similar results were demonstrated for rat 
lung, which was used as a positive control for APJ receptor expression (58). In 
immunofluorescence studies using confocal microscopy, APJ receptor protein was detected in 
cerebral arteries and localized to the smooth muscle cell layer, as well as endothelium (Figure 
2C.1-C.3). An isotype negative control antibody demonstrated a lack of non-specific binding of 
secondary antibody in the absence of primary APJ receptor antibody (Figure 2C.5). Rat lung tissue 
(positive control) demonstrated staining for APJ receptors on bronchial epithelium (Figure 2C.6). 
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Fig. 2. Expression and localization of APJ receptors. 
(A) Representative immunoblot showing expression of APJ receptor (APJR) protein in 
homogenates from rat cerebral arteries (Lane 1) and lung tissue (Lane 2); β-actin was used as a 
loading control. The immunoblots shown are representative of data obtained from five different 
animals.  (B) Bar graph showing relative mRNA expression of APJ receptor, represented as ΔCt 
values relative to β-actin. Data are presented as mean ± SEM (n=3). (C) Representative 
immunofluorescence images of: (1) APJ receptors (red fluorescence), (2) smooth muscle cell actin 
(green fluorescence), (3) merged image showing co-localized areas in smooth muscle cells (yellow 
fluorescence) and endothelium (red fluorescence) in rat cerebral artery; (4) differential interference 
contrast image of rat cerebral artery; (5) isotype negative control for APJ receptor antibody with 
nuclear staining (blue fluorescence); and (6) APJ receptors (red fluorescence) with nuclear staining 
(blue fluorescence) in rat bronchial epithelium (positive control). The images are representative of 
those obtained from three different animals. Scale bar, 20 μm.  
Vascular Relaxation Studies 
In cerebral arteries contracted with 5-HT (10-7 M), addition of increasing concentrations of 
apelin (10-8 - 3 x 10-6 M) to the preparations had no effect on vasomotor tone in rings with or 
without endothelium (Figure 3). Likewise, these concentrations of apelin had no effect on resting 
tone in quiescent cerebral arterial rings (data not shown). 
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Fig. 3. Lack of direct effect of apelin on rat isolated cerebral arteries. 
(A) Representative original tracings of isometric tension recordings from rat isolated cerebral 
arteries (with and without endothelium) in response to cumulative addition of increasing 
concentrations of apelin, followed by bradykinin (BK; 10-7 M) and diltiazem (10-5 M). (B) Mean 
data demonstrating a lack of vasomotor effect of apelin on cerebral arteries with (E+) and without 
(E-) endothelium.  Data are expressed as a percentage of the initial increase in tension induced by 
5-HT (10-7 M).  Each point represents the mean ± S.E.M. (n=5). 
 
The NO-donor, DEA NONOate (10-9 - 10-5 M), caused concentration-dependent relaxation 
of endothelium-denuded cerebral arteries contracted with 5-HT (10-7 M) (Figure 4). The 
concentration-response curve to DEA NONOate was inhibited in the presence of apelin (10-7 M) 
(Figure 4A); the pD2 values for the responses to DEA NONOate shown in Figure 3A were 6.92 ± 
0.20 vs. 6.13 ± 0.08, in the absence and presence of apelin, respectively (p<0.05). The BKCa 
channel blocker, iberiotoxin (10-7 M), had an inhibitory effect on the response to DEA NONOate 
that was similar to that observed with apelin (Figure 4B). The corresponding pD2 values for DEA 
NONOate were 6.98 ± 0.21 vs. 6.14 ± 0.13, without and with iberiotoxin, respectively (p<0.05).  
Treatment with a combination of apelin (10-7 M) plus iberiotoxin (10-7 M) had no greater inhibitory 
effect on DEA NONOate-induced relaxation of isolated cerebral arteries (pD2 = 6.19 ± 0.07; n=6) 
than apelin or iberiotoxin alone (Figure 9A).   
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Fig. 4. DEA NONOate-induced relaxation of isolated cerebral arteries is inhibited by apelin and 
iberiotoxin. 
Log concentration-response curves for DEA NONOate in producing relaxation of endothelium-
denuded cerebral arteries, in the absence and presence of: (A) apelin (10-7 M); pD2 = 6.92 ± 0.20 
vs. 6.13 ± 0.08, in the absence and presence of apelin, respectively (p<0.05); and (B) iberiotoxin 
(IBTx; 10-7 M); pD2 = 6.98 ± 0.21 vs. 6.14 ± 0.13, without and with IBTx, respectively (p<0.05).  
Data are expressed as a percentage of the initial increase in tension induced by 5-HT (10-7 M).  
Each point represents the mean ± S.E.M. (n=5-10). 
 
The APJ receptor antagonist, F13A (10-7 M), which had no effect of its own on the response 
to DEA NONOate, abolished the inhibitory effect of apelin on DEA NONOate-induced relaxation 
(Figure 5). 
 
Fig. 5. The APJ receptor antagonist, F13A, inhibits the effect of apelin on cerebral artery relaxation 
induced by DEA NONOate.  
Bar graph representing the effect of apelin (10-7 M) and F13A (10-7 M), alone or in combination, 
on DEA NONOate (10-6 M)-induced relaxation of cerebral arteries.  Experiments with inhibitors 
were conducted in parallel with untreated control rings taken from the same animal. Each point 
represents the mean ± S.E.M. (n=6), * p<0.05 vs. DEA NONOate alone. 
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Experiments were then performed in order to determine the effect of apelin on cerebral 
arterial relaxations evoked by endogenous NO. The endothelium-dependent vasodilator, 
bradykinin, was used in these experiments since bradykinin-induced relaxation of rat cerebral 
arteries is mediated by endothelium-derived NO (Figure 6) (85, 86).  
 
Fig. 6. Bradykinin-induced, endothelium-dependent relaxation of isolated cerebral arteries is 
inhibited by apelin and iberiotoxin.  
Log concentration-response curves for bradykinin in producing relaxation of endothelium-intact 
cerebral arteries, in the absence and presence of: (A) nitro-l-arginine (NLA; 3 x 10-5 M); (B) ODQ 
(10-5 M); and (D) indomethacin (10-5 M). Data are expressed as a percentage of the initial increase 
in tension induced by 5-HT (10-7 M).  Each point represents the mean ± S.E.M. (n=6). 
 
The results of these experiments are shown in Figure 7, which demonstrates that 
bradykinin-induced relaxation of endothelium-intact cerebral arteries was inhibited in the presence 
of apelin (10-7 M), as evidenced by a significant difference in pD2 values for bradykinin (7.76 ± 
0.20 vs. 7.03 ± 0.12, in the absence and presence of apelin, respectively; p<0.05) and a reduction 
in the maximal relaxation response (Figure 7A). Iberiotoxin (10-7 M) had an inhibitory effect on 
the bradykinin concentration-response curve that was similar to that observed with apelin; the pD2 
values for bradykinin were 8.02 ± 0.21 vs. 7.19 ± 0.22 in the absence and presence of iberiotoxin, 
respectively (p<0.05). The effect of combined treatment with apelin (10-7 M) plus iberiotoxin (10-
7 M) on bradykinin-induced relaxation of isolated cerebral arteries was similar to that observed 
with either inhibitor alone (pD2 = 7.15 ± 0.17; n=6) (Figure 9B). 
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Fig. 7. Bradykinin-induced, endothelium-dependent relaxation of isolated cerebral arteries is 
inhibited by apelin and iberiotoxin.  
Log concentration-response curves for bradykinin in producing relaxation of endothelium-intact 
cerebral arteries, in the absence and presence of: (A) apelin (10-7 M); pD2 = 7.76 ± 0.20 vs. 7.03 ± 
0.12, in the absence and presence of apelin, respectively (p<0.05); and (B) iberiotoxin (IBTx; 10-7 
M); pD2 = 8.02 ± 0.21 vs. 7.19 ± 0.22, in the absence and presence of IBTx, respectively (p<0.05).  
Data are expressed as a percentage of the initial increase in tension induced by 5-HT (10-7 M).  
Each point represents the mean ± S.E.M. (n=6-7). 
 
As observed in the experiments with DEA NONOate, F13A (10-7 M) had no effect on the 
response to bradykinin, but abolished the inhibitory effect of apelin on bradykinin-induced 
relaxation (Figure 8). 
 
Fig. 8. The APJ receptor antagonist, F13A, inhibits the effect of apelin on cerebral artery relaxation 
induced by bradykinin.  
Bar graph representing the effect of apelin (10-7 M) and F13A (10-7 M), alone or in combination, 
on bradykinin (10-6 M)-induced relaxation of cerebral arteries. Experiments with inhibitors were 
conducted in parallel with untreated control rings taken from the same animal. Each point 
represents the mean ± S.E.M. (n=6-12), * p<0.05 vs. Bradykinin alone. 
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Fig. 9.  Effect of combined treatment with apelin plus iberiotoxin on cerebral artery relaxation to 
DEA NONOate and bradykinin. 
Bar graph representing effects of apelin (10-7 M) and iberiotoxin (10-7 M), alone or in combination, 
on (A) DEA NONOate (3 x 10-7 M) and (B) bradykinin (10-6 M)-induced relaxation of cerebral 
arteries. Each point represents the mean ± S.E.M. (n=5-8), *p<0.05 vs. DEA NONOate or 
bradykinin alone. 
 
The effects of apelin on relaxations induced by the BKCa channel openers, NS1619 and 
BMS 191011 (87), and the KATP channel opener, levcromakalim (88), were also determined. At 
equieffective concentrations of the K channel openers, apelin inhibited the responses to NS1619 
and BMS 191011 (Figure 10A and 10B), but had no effect on levcromakalim-induced relaxation 
of endothelium-denuded cerebral arteries (Figure 10C). 
 
Fig. 10. Apelin selectively inhibits relaxation of cerebral arteries in response to BKCa channel 
activators.  
Bar graph representing the effects of apelin (10-7 M) on relaxation of cerebral arteries in response 
to: (A) NS1619 (10-6 M); (B) BMS 191011 (3 x 10-6 M); and (C) levcromakalim (3 x 10-6 M). 
Each point represents the mean ± S.E.M. (n=6), *p<0.05 vs. NS1619 or BMS 191011 in the 
absence of apelin. 
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Electrophysiology Studies 
DEA NONOate (10-5 M) caused a significant increase in whole-cell BKCa channel current 
measured in freshly isolated cerebral arterial smooth muscle cells (Figure 11). The DEA 
NONOate-induced increase in BKCa channel current was nearly abolished by apelin (10
-7 M) 
(Figure 11A-E). As was observed in the vascular relaxation studies, the inhibitory effect of apelin 
on the response to DEA NONOate was mimicked by iberiotoxin (10-7 M) (Figure 11F). In the 
presence of F13A (10-7 M), apelin (10-7 M) had no effect on the DEA NONOate-induced increase 
in BKCa channel current (peak current density (+80 mV) = 79.3 + 7.2 with DEA NONOate alone 
versus 77.7 + 5.5 pA/pF with DEA NONOate in the presence of apelin plus F13A; p>0.05; n=6) 
(Figure 12) 
 
Fig. 11. Apelin inhibits DEA NONOate-induced increase in whole cell BKCa currents.   
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV before and after treatment with DEA NONOate (DEA, 10-5 M) with and without 
apelin (10-7 M) or Iberiotoxin (IBTx, 10-7 M). A-D: Representative tracings depicting the 
sequential current recordings from a single smooth muscle cell in (A) control conditions followed 
by (B) DEA (10-5 M, 2 min); (C) apelin (10-7 M, 5 min) and (D) combination of DEA (10-5 M) and 
apelin (10-7 M). E: Summary I-V curve plot of BKCa currents at baseline and after treatment with 
DEA (10-5 M), with or without apelin (10-7 M). F: Bar graph summarizing the effect of Iberiotoxin 
(10-7 M, 5 min) on DEA (10-5 M)-induced average current density (pA/pF) at +80mV. Values are 
represented as mean ± SEM (n=6). *p<0.05 vs control current density; #p<0.05 vs DEA NONOate-
induced current density. 
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Fig. 12. F13A abolishes apelin-induced inhibitory effects on whole cell BKCa currents.  
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV before and after treatment with DEA NONOate (DEA, 10-5 M) with and without 
alone or combined presence of apelin (10-7 M) and F13A (10-7M). Values are represented as mean 
± SEM (n=6). *p<0.05 vs control current density. 
 
Likewise, apelin (10-7 M) also suppressed the NS1619-induced increase in BKCa channel 
current in isolated cerebral arterial smooth muscle cells (Figure 13).  
 
Fig. 13. Apelin inhibits NS1619-induced whole cell BKCa currents.   
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV before and after the treatment with NS1619 (10-5 M), with and without apelin 
(10-7 M) or Iberiotoxin (IBTx, 10-7 M). A-D: Representative tracings depicting the sequential 
current recordings from a single smooth muscle cell in (A) control conditions followed by (B) 
NS1619 (10-5 M, 2 min); (C) apelin (10-7 M, 5 min) and (D) combination of NS1619 (10-5 M) and 
apelin (10-7 M). E: Summary I-V curve plot of BKCa currents at baseline and after treatment with 
NS1619 (10-5 M), with or without apelin (10-7 M). F: Bar graph summarizing the effect of 
Iberiotoxin (10-7 M, 5 min) on NS1619 (10-5 M)-induced average current density (pA/pF) at 
+80mV. Values are represented as mean ± SEM (n=6). *p<0.05 vs control current density; #p<0.05 
vs DEA-induced current density. 
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Cyclic GMP Measurements 
DEA NONOate (10-6 M) and bradykinin (10-6 M) each caused a significant increase in 
intracellular cyclic GMP levels in cerebral arteries (Figure 14). Incubation of cerebral arteries with 
apelin (10-7 M) had no effect on the increases in cyclic GMP levels evoked by either DEA 
NONOate (Figure 14A) or bradykinin (Figure 14B). 
 
Fig. 14. Lack of effect of apelin on DEA NONOate- and bradykinin-induced increases in 
intracellular cyclic GMP levels. 
Bar graphs representing the effects of apelin (10-7 M) on the increase in cyclic GMP levels in 
response to: (A) DEA NONOate (10-6 M) (DEA), and (B) bradykinin (10-6 M) (BK).  Values are 
represented as mean ± SEM (DEA n=6; BK n=5). *p<0.05 vs basal levels. 
 
Discussion 
The major finding of the present study is that receptors for apelin (i.e. APJ receptors) are 
expressed in cerebral arteries and that activation of these receptors on vascular smooth muscle 
cells inhibits NO-induced relaxation. This conclusion, which identifies a previously unrecognized, 
novel action of apelin in blood vessels, is based on the findings that: 1) APJ receptor mRNA and 
protein are expressed in cerebral arteries; 2) APJ receptor protein co-localizes with smooth muscle 
cell actin in the arterial wall; 3) apelin inhibits relaxation of cerebral arteries in response to 
endothelium-derived NO, as well as an NO-donor; and 4) the inhibitory effects of apelin on NO-
induced relaxation of cerebral arteries are abolished by an APJ receptor antagonist. Moreover, the 
findings indicate that apelin inhibits relaxation of cerebral arteries to NO by attenuating NO-
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induced increases in BKCa current in the arterial smooth muscle cells. When taken together with 
the observation that apelin failed to cause relaxation in cerebral arteries, these actions of apelin 
could be expected to result in a net increase in cerebral vasomotor tone. 
APJ receptors have been identified in several blood vessels throughout the cardiovascular 
system. For example, immunocytochemical and autoradiographic studies have detected APJ 
receptors in human saphenous vein, as well as coronary, internal mammary, radial, and pulmonary 
arteries, and in rat aorta, coronary, and pulmonary arteries (5, 18, 79). The results of the present 
study add to the current body of knowledge by demonstrating for the first time that APJ receptor 
gene transcripts and proteins are expressed in cerebral arteries. Moreover, immunofluorescence 
co-localization studies indicate that APJ receptors are present on both vascular smooth muscle and 
endothelial cells in the cerebral arterial wall, suggesting the possibility that APJ receptors may be 
involved in the local regulation of cerebral artery vasomotor tone. 
An increasing body of evidence from both in vivo and in vitro studies supports a functional 
role for APJ receptors in regulating vascular tone. Intravenous administration of exogenous apelin 
has been shown to cause both an increase and a decrease in mean arterial blood pressure (39, 54, 
75), as well as a decrease in preload consistent with a venodilator effect (39, 89). Apelin also 
increases forearm blood flow and coronary blood flow in humans (52, 76). In isolated arterial rings 
from several sources, apelin causes endothelium-dependent relaxations under normal conditions 
(22, 38), whereas vascular smooth muscle contraction is observed in blood vessels in which the 
endothelium has been removed or damaged (22, 67). Nonetheless, apelin itself failed to cause 
either contraction or relaxation of isolated cerebral arteries, regardless of the status of the 
endothelium and despite the presence of APJ receptors on vascular smooth muscle and endothelial 
cells in these arteries. These results demonstrate that apelin itself does not directly alter vasomotor 
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tone in cerebral arteries, in contrast to its actions reported in other arteries studied thus far; 
however, the lack of a direct effect does not preclude the possibility that apelin could indirectly 
regulate vasomotor tone by modulating the actions of other vasoactive substances (e.g. NO), or 
perhaps play a role in other functions of vascular cells in the arterial wall (e.g. proliferation, 
permeability). 
A key finding of the present study is that despite having no measurable direct effect on 
cerebrovascular tone, apelin inhibited relaxations in response to bradykinin, an endothelium-
dependent vasodilator that acts via the release of NO from endothelial cells in cerebral arteries (85, 
86), and to DEA NONOate, an exogenous NO-donor (90). Since APJ receptors are expressed on 
cerebral artery endothelial cells, one potential site of action for apelin, at least with regard to 
endogenously produced NO, could be inhibition of endothelial nitric oxide synthase (eNOS); 
however, the only published reports regarding the regulation of eNOS by apelin indicate that the 
peptide increases, rather than inhibits, eNOS activity (40, 43). Although an effect of apelin on 
eNOS in cerebral arteries cannot be ruled out by the present study, the observation that apelin also 
inhibits NO-induced relaxation in response to DEA NONOate, which acts independently of the 
endothelium, suggests a site of action other than or in addition to eNOS. These results, together 
with data from the molecular studies indicating that cerebral arterial smooth muscle cells express 
APJ receptors, are consistent with an inhibitory effect of apelin at the level of the vascular smooth 
muscle, which is the primary site of action for the relaxing effect of NO (91, 92). Moreover, that 
the inhibitory effects of apelin on both the functional and electrophysiological responses to NO 
were blocked by pharmacologic inhibition with F13A, an APJ receptor antagonist (11), strongly 
suggests that activation of APJ receptors on smooth muscle cells mediates this effect of apelin in 
cerebral arteries. 
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The molecular mechanism by which APJ receptor activation by apelin causes impaired 
relaxation to NO likely involves inhibition of NO-induced increases in BKCa channel current in 
cerebral smooth muscle cells. Activation of BKCa channels leads to vascular smooth muscle cell 
hyperpolarization and relaxation (93, 94) and BKCa channels are abundantly expressed in cerebral 
arterial smooth muscle cells (61), where they play a pivotal role in regulating vascular tone (95).  
In cerebral arteries of the rat, NO-induced relaxation is mediated in part by increased BKCa channel 
activity and in part by increased formation of intracellular cyclic GMP resulting from activation 
of soluble guanylyl cyclase (51, 96, 97). Since apelin had no effect on the increase in cyclic GMP 
levels evoked by either bradykinin or DEA NONOate it is unlikely that inhibition of guanylyl 
cyclase underlies the ability of apelin to impair NO-induced relaxation in cerebral arteries. On the 
other hand, a role for BKCa channels in the effect of apelin on NO-induced relaxation is supported 
by several pieces of evidence, including: 1) apelin inhibited the increases in BKCa current induced 
by the NO-donor, DEA NONOate, and the synthetic BKCa channel activator, NS1619, in cerebral 
arterial smooth muscle cells; 2) the effects of apelin on both the functional and electrophysiological 
responses to NO were mimicked by iberiotoxin, a potent and selective BKCa channel blocker (98); 
3) combined treatment with apelin plus iberiotoxin had no greater effect on NO-induced relaxation 
than either inhibitor alone, consistent with a shared mechanism of action for apelin and iberiotoxin; 
and 4) apelin inhibited relaxation of endothelium-denuded cerebral arteries in response to the BKCa 
channel activators, BMS 191011 and NS1619 (87, 99). With regard to the latter findings, it has 
been reported that in addition to activating BKCa channels, NS1619 also inhibits plasma membrane 
L-type calcium channels (100); however, in the present study this potential limitation was 
minimized by using two chemically distinct BKCa channel activators, as well as a concentration of 
NS1619 that has little effect on calcium currents and is known to relax cerebral arteries in a manner 
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that is nearly entirely due to BKCa channel activation (100, 101). Moreover, apelin had no effect 
on relaxation to the selective KATP channel opener, levcromakalim, thus providing further support 
for the view that apelin selectively inhibits responses that are mediated via BKCa channels in 
cerebral arterial smooth muscle cells. Taken together, the data indicate that the effect of apelin on 
BKCa channels is sufficient to meaningfully impair cerebral arterial relaxation evoked by NO as 
well as other BKCa channel-activating molecules. 
The finding that apelin inhibits NO-induced relaxation in cerebral arteries is in contrast to 
its putative beneficial vasodilator effects reported in several peripheral arteries. Given the 
considerable heterogeneity known to exist among blood vessels from different origins in terms of 
their reactivity to vasoactive agents it is not necessarily surprising that cerebral arteries may differ 
from peripheral arteries in their response to apelin. In the rat, for example, the pineal hormone, 
melatonin, is a potent vasoconstrictor in isolated cerebral arteries (101) but causes relaxation of 
isolated aorta and caudal artery (102, 103). The reason(s) for the divergent responses to apelin 
among different blood vessels are not yet readily apparent, but possible explanations could include: 
1) differences in the subtype of APJ receptor expressed in smooth muscle of cerebral vs peripheral 
arteries; however, it should be noted that there are no reports in the literature of multiple APJ 
receptor subtypes; 2) differences in the intracellular signaling pathways coupled to APJ receptor 
activation in cerebral versus peripheral arteries; and 3) differences in the role of BKCa channels in 
NO-induced relaxation among blood vessels. 
The apelin/APJ receptor-signaling axis is generally considered to play a protective role in 
the cardiovascular system, with suggested benefits in disorders such as ischemia-reperfusion 
injury, heart failure, and pulmonary hypertension (42, 81, 104). Although apelin may have 
protective vasodilator effects in certain arteries (e.g. pulmonary vascular bed), it is evident from 
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the present study that, in cerebral arteries, the net effect of APJ receptor activation could adversely 
affect cerebrovascular function. This may present an important caveat when exploring the 
cardiovascular efficacy of systemically administered APJ receptor agonists.  Indeed, apelin-like 
analogs are now in preclinical development as potential therapeutic agents for myocardial 
infarction and ischemia-reperfusion injury (47), and apelin itself is currently being administered 
to patients in clinical trials because of its putative beneficial effects on cardiac function and the 
pulmonary circulation (76, 105). The cerebrovascular consequences of such drugs may be 
particularly significant in certain patients, inasmuch as a single nucleotide polymorphism in the 
gene encoding the human APJ receptor, which results in increased apelin/APJ receptor signaling, 
has recently been identified and is associated with an increased risk of brain infarction (106). Since 
impaired vasodilation is a hallmark characteristic of the vascular dysfunction that occurs in many 
forms of cardiovascular disease (92), it is interesting to note that endogenous apelin levels are 
elevated in conditions such as obesity and diabetes (107-109), which are major risk factors for 
stroke and other cerebrovascular disorders (110).  
In summary, apelin activates APJ receptors in cerebral arterial smooth muscle cells, 
resulting in inhibition of BKCa currents and impaired relaxation to endogenous and exogenous NO 
in cerebral arteries. Whether the ability of apelin to regulate vasomotor tone by inhibiting NO-
induced relaxation is unique to the cerebral circulation is not yet clear, but given the pivotal role 
of NO in controlling vascular function, it will be important to determine if this novel effect of 
apelin is observed in other blood vessels. The potential for adverse effects on the cerebral 
circulation to occur with the use of APJ receptor-activating drugs may merit further consideration 
in future studies.  
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CHAPTER 3. VASCULAR EFFECTS OF APELIN IN CORONARY 
ARTERIES: COMPARISON WITH ANOTHER NITRIC OXIDE 
DEPENDENT VASODILATOR, ACETYLCHOLINE 
Introduction 
Apelin and APJ receptor are widely expressed in cardiovascular system including 
cardiomyocytes (4) and vasculature (5, 18), and can regulate vascular tone through both autocrine 
and paracrine mechanisms (74). APJ receptors are detected on endothelial and vascular smooth 
muscle cells within many blood vessel walls (5, 18) and this vascular distribution propose 
involvement of apelin-APJ axis in the regulation of vascular tone by endothelium dependent 
vasodilation (38, 43) and/or endothelium independent vasoconstriction (67). Apelin increases 
coronary blood flow and vascular functions of apelin are preserved during heart failure (76), 
suggesting enormous potential of apelin in restoring vascular functions during coronary artery 
diseases. Further, intravenous infusion of apelin increases preload consistent with a vasodilator 
effect (39, 89). Although pathophysiological alterations in apelin signaling during cardiovascular 
diseases are still under investigation (111, 112), but exogenous apelin is shown to improve 
hemodynamic and vascular functions during cardiovascular and metabolic diseases (41, 113-115).  
Apelin causes vasodilation in most of the peripheral arteries, studied thus far, in part by 
nitric oxide dependent pathways (22, 38). Moreover, apelin increases forearm blood flow (52) and 
decreases mean arterial pressure (19, 55) via nitric oxide dependent pathways. Although current 
body of the knowledge demonstrates involvement of nitric oxide in apelin-induced vasoactive 
effects, the possible downstream signaling mechanism(s) is yet to be identified.   
Endothelial nitric oxide is an important regulator of vascular tone and can activates 
multiple mediators including soluble guanylate cyclase to synthesize cGMP (91, 116), SERCA 
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(50, 117) and BKCa channels (48, 49). The ultimate endpoint for all signaling mechanism(s) is 
relaxation of vascular smooth muscle and vasodilation. However, a better understanding of 
relaxation pathways can provide better opportunities and models for apelin based therapeutic 
strategies for treatment of cardiovascular diseases. Thus to reduce critical gaps in the knowledge, 
the present study was aimed to identify possible mediators involved in apelin-induced relaxation 
in coronary arteries and compare it with a known endothelium dependent vasodilator, 
acetylcholine. 
The present results demonstrate that apelin by activating endothelial APJ receptors can 
cause nitric oxide dependent relaxation of coronary arteries, likely through direct activation of 
smooth muscle BKCa channels. Moreover, different physiological stimuli i.e. apelin and 
acetylcholine can increase endothelial nitric oxide formation to activate different downstream 
mediators to relax coronary arteries. 
Materials and Methods 
Animals and Tissue Preparation:  Experiments were performed on tissues isolated from 
12-week-old male Sprague-Dawley rats (Envigo RMS, Indianapolis, IN). Rats were housed at 22 
± 2°C on a 12 h-12 h light-dark cycle and provided with food and water ad libitum. All animal 
protocols were approved by the North Dakota State University Institutional Animal Care and Use 
Committee. Rat hearts were isolated from animals anesthetized with isoflurane and placed into 
ice-cold physiological salt solution (PSS) with the following composition (in mM): 118.9 NaCl; 
4.7 KCl; 2.5 CaCl2; 1.2 MgSO4.7H2O; 1.2 KH2PO4; 25.0 NaHCO3; 5.5 glucose and 0.03 EDTA. 
Epicardial coronary arteries were dissected and cleaned of surrounding tissues.  
Western Immunoblotting:  After collection, coronary arteries were immediately frozen 
in liquid nitrogen. Tissues were homogenized in lysis buffer and supplemented with a protease and 
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phosphatase inhibitor cocktail (FabGennix International, Frisco, TX) at 4°C using an IKA Ultra-
Turrax T8 homogenizer (IKA Works Inc., Wilmington, NC). Tissue homogenates were kept on 
ice for 10 min and then centrifuged at 10000g for 10 min.  Supernatant was collected, and protein 
determination was performed using a Pierce BCA protein estimation kit (ThermoFisher Scientific, 
Waltham, MA). Aliquots of supernatant containing equal amounts of protein (40 μg) were 
separated on 7.5-10% polyacrylamide gel by SDS-polyacrylamide gel electrophoresis, and 
proteins were electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, 
Hercules, CA). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS, pH 7.4) 
and incubated overnight at 4°C with a primary antibody specific for APJ receptors using a dilution 
of (1:200) (Santa Cruz Biotechnology Inc.). Membranes were washed three times for 10 min using 
TBS-Tween 20 and incubated with a horseradish peroxidase-linked secondary antibody (Santa 
Cruz Biotechnology Inc.).  To ensure equal loading, the blots were analyzed for β-actin expression 
using an anti-actin antibody (Santa Cruz Biotechnology Inc.). Immuno-detection was performed 
using an enhanced chemiluminescence light detection kit (ThermoFisher Scientific). 
RT-qPCR:  Freshly isolated arteries were immediately frozen in liquid nitrogen and total 
RNA was isolated using an RNeasy Mini kit, according to the manufacturer’s protocol (Qiagen, 
Germantown, MD). The concentration and purity of RNA was determined using a 
spectrophotometer (Nanodrop Technologies, Wilmington, DE). cDNA was synthesized using 50 
ng of RNA and an iScript cDNA synthesis kit (Bio-Rad). A Sybr Green expression assay was used 
to determine expression of APJ receptors, with β-actin used as a housekeeping gene (Bio-Rad). 
The following primers (synthesized by Invitrogen, Carlsbad, CA) were used:   
APJ receptor – forward: 5’-ACAAGACATGTGCCATTGGA-3’; reverse: 5’-
TCTCCCAGAAGCCTCCTACA-3’; β-actin – forward: 5’-GTCGTACCACTGGCATTGTG-3’; 
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reverse: 5’-TCTCAGCTGTGGTGGTGAAG-3’.  Real-time RT-PCR reaction conditions were 
95°C for 10 min, followed by 40 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 30 s. 
Immunofluorescence microscopy:  Freshly isolated coronary arteries were fixed in 10% 
formalin solution, processed and embedded in paraffin blocks. Paraffin blocks were sectioned at 5 
μm and mounted onto ProbeOn Plus microscopic slides (ThermoFisher Scientific). Sections were 
fixed by heating at 60°C for 30 min. Nonspecific antibody binding was blocked with normal serum 
[10% w/v; in TBS] for 1 h at room temperature. Sections were incubated overnight at 4°C in 1% 
serum containing a primary antibody against APJ receptors (Abcam, Cambridge, MA), smooth 
muscle actin (Santa Cruz Biotechnology) and/or PECAM-1 (Santa Cruz Biotechnology).  For co-
localization, double immunofluorescent staining was performed by incubating the tissue sections 
with more than one primary antibody at the same time. Detection of the primary antibodies against 
the APJ receptor, smooth muscle actin and PECAM-1 was accomplished using Texas red-
conjugated (goat anti-rabbit IgG; Invitrogen, Carlsbad, CA), Alexa Fluor-488 (donkey anti-mouse 
IgG; Santa Cruz Biotechnology) and Alexa Fluor-555 (donkey anti-goat IgG; Santa Cruz 
Biotechnology) secondary antibodies, respectively. Rat lung tissue was used as positive control 
for APJ receptor detection (58).  All negative controls were incubated with 1% serum solution 
overnight followed by secondary antibodies. All dilutions and thorough washes between stages 
were performed using TBS containing Triton X-100 [0.3% (v/v)] unless otherwise stated. Sections 
were drained by blotting with filter paper, and a drop of mounting medium containing an anti-fade 
reagent (Vector Laboratories, Burlingame, CA) was added to the slides. Images of the sections 
were obtained using an Olympus confocal laser-scanning microscope (Olympus, Tokyo, Japan).  
The images were generated using Olympus FluoView FV300 (v. 4.3) confocal software. 
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Vascular Functional Studies:  Arterial rings (120-150 µm; 1.2 mm in length) were 
suspended in wire myographs (DMT, Aarhus, Denmark) for isometric tension recording. The 
myograph chambers were filled with PSS (5 ml), which was continuously aerated with 95% O2/5% 
CO2 and maintained at 37°C throughout the experiment. The vessels were stretched to using DMT 
normalization guide, where arteries were stretched up to 6 mN by a sequential stretching of 1.5 
mN for 5 min (until 6 mN). Then vessels were allowed to stabilize for 30-40 min with intermittent 
washings. Vessel reactivity was confirmed by evoking a response to KCl (60 mM). In some 
vessels, the endothelium was removed by gently rubbing the intimal surface with a human hair. 
The presence or absence of endothelium was confirmed by measuring relaxation in response to the 
endothelium-dependent vasodilator, acetylcholine (10-6 M). Responses to the vasodilators used in 
this study were obtained in arterial rings contracted with 5-HT (10-7 M). Inhibitors were added to 
the myograph chamber 20 min prior to contraction with 5-HT and the inhibitors remained in 
contact with the tissues for the remainder of the experiment. Experiments with inhibitors were 
conducted in parallel with control rings taken from the same animal. 
Coronary Endothelial Cells (ECs) Isolation:  Endothelial cells were isolated from 
coronary arteries as previously described (118) with minor modifications. Briefly, coronary 
arteries were digested in dissociation solution (55 mM NaCl, 80 mM Na-glutamate, 6 mM KCl, 2 
mM MgCl2, 0.1 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.3) containing Worthington 
neutral protease (0.5 mg/mL) and elastase (0.5 mg/mL) for 60 minutes at 37°C. Then, Collagenase 
(Worthington type II, 0.5 mg/mL) was added to the same enzyme solution and digestion was 
continued for 2 minutes. The artery was removed and placed back in the dissociation solution 
without enzymes for an additional 10 min before trituration with a polished Pasteur pipette to yield 
single endothelial cells suspension. 
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Real-Time NO Imaging:  Freshly isolated ECs were allowed to attach in eight well 
LabTek chambers (Thermo Fisher Scientific, Waltham, MA) for 3-4 hours. The cells were then 
loaded with NO-sensitive fluorescent dye 4,5-diaminofluorescein diacetate (DAF-2 DA; Thermo 
Fisher Scientific, Waltham, MA; 5 μM; 60 min at room temperature). The real time imaging was 
performed using an Olympus confocal laser-scanning microscope (Olympus, Tokyo, Japan) with 
a 40x numerical aperture oil immersion lens (with excitation at 488 nm and emission at 515 nm). 
All experiments were carried out at room temperature in HBSS. The effect of various agonists and 
inhibitors on intracellular NO level was obtained in paired experiments. In experiments with 
inhibitors, NLA (3 x 10-5 M) or F13A (10-7 M) was added to the chamber for 10 min before addition 
of apelin (10-7 M) or acetylcholine (10-6 M). ECs were isolated from 4-6 animals (each animal on 
different day) and 2-3 cells were analyzed for each treatment from each animal. 
Cyclic GMP Estimation:  Competitive ELISA method was used to measure cGMP levels 
in coronary arteries. Arterial segments were equilibrated in PSS for at least 30 min at 37°C. After 
the equilibration period, arterial segments were treated with apelin (10-7 M, 5 min) or acetylcholine 
(ACh; 10-6 M, 5 min). In some experiments, arterial segments were pretreated for 20 min with 
NLA (3 x 10-5 M) or ODQ (10-5 M), before being exposed to agonists. After drug treatments, 
segments were immediately frozen in liquid nitrogen and homogenized with an IKA Ultra, Turrax-
T8 homogenizer (IKA Works) at 4°C in 0.1 M hydrochloric acid. Tissue homogenates were 
centrifuged for 10 min at ≥600 g. cGMP and total protein content were determined in the 
supernatant as per the direct cGMP enzyme immunoassay kit (Assay Design, Ann Arbor, MI) and 
Pierce BCA protein assay kit (ThermoFisher Scientific) respectively. cGMP levels are expressed 
as picomoles per microgram of protein. 
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Coronary Smooth Muscle Cell Isolation:  Enzymatic isolation of single vascular smooth 
muscle cells was carried out as described previously, with brief modification (30). Arteries were 
placed in cell isolation solution of the following composition (in mM): 60 NaCl, 80 Na-glutamate, 
5 KCl, 2 MgCl2, 10 glucose, and 10 HEPES (pH 7.2). Arterial segments were initially incubated 
in 1.2 mg/ml papain (Worthington) and 1.0 mg/ml dithioerythritol (Sigma Aldrich) for 17 min at 
37°C and then in 1.2 mg/ml type II collagenase (Worthington) and 0.5 mg/ml elastase 
(Worthington) for 12 min at 37°C.  The digested segments were washed three times in ice-cold 
cell isolation solution and incubated on ice for 30 min. After this incubation period, vessels were 
triturated to liberate smooth muscle cells and stored in ice-cold cell isolation solution for use.  
Smooth muscle cells were studied within 6 h following isolation. 
Electrophysiological Recording:  Isolated smooth muscle cells were placed into a 
recording chamber (Warner Instruments, Hamden, CT) and allowed to adhere for 20 min at room 
temperature. Whole cell currents were recorded using an AxoPatch 200B amplifier equipped with 
an Axon CV 203BU headstage (Molecular Devices). Current data were collected and analyzed 
with pCLAMP 10.0 software (Molecular Devices, Sunnywale, CA). The patch electrodes (3-4 
MΩ) were fabricated from 1.5-mm borosilicate glass capillaries. Smooth muscle cells were 
superfused at a rate of 2.0 ml/min with a solution containing (in mM) 145 NaCl, 5.4 KCl, 1.8 
CaCl2, 1 MgCl2, 5 HEPES, 10 glucose; pH 7.4 (NaOH).  Patch pipettes were filled with internal 
pipette solution contained (in mM) 145 KCl, 5 NaCl, 0.37 CaCl2, 2 MgCl2, 10 HEPES, 1 EGTA, 
7.5 Glucose; pH 7.2 (KOH). All drugs were diluted in fresh bath solution and perfused into the 
experimental chamber. Voltage-activated currents were filtered at 2 kHz and digitized at 10 kHz, 
and capacitative and leakage currents were subtracted digitally. Series resistance and total cell 
capacitance were calculated from uncompensated capacitive transients in response to 10 ms 
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hyperpolarizing step pulses (5 mV), or obtained by adjusting series resistance and whole-cell 
capacitance using the Axopatch 200B amplifier control system. Standard recording conditions for 
BKCa were achieved by stepping in 10 mV increments from a holding potential of -60 to +80 mV. 
BKCa currents were expressed as current density (current divided by its capacitance). 
Drugs:  The following drugs were used: acetylcholine, diethylamine NONOate (DEA 
NONOate), sodium nitroprusside (SNP), diltiazem, 5-hydroxytryptamine (5-HT), indomethacin, 
PEG-catalase, DT-2 trifluoroacetate salt, nitro-l-arginine (NLA) and glyburide (Sigma Chemical, 
St. Louis, MO); iberiotoxin, and 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (Tocris, 
Ellisville, MO); apelin-13, and F13A (H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-
Ala-OH trifluoroacetate salt) (Bachem, Torrance, CA) and cyclopiazonic acid (Abcam, 
Cambridge, MA). Drug solutions were prepared fresh daily, kept on ice, and protected from light 
until used. All drugs were dissolved in double-distilled water with the exception of ODQ and 
cyclopiazonic acid which were dissolved initially in DMSO, indomethacin, which was dissolved 
initially in 1 mM sodium carbonate, and glyburide, which was dissolved initially in 0.1 N NaOH  
prior to further dilution in double-distilled water. Drugs were added to the myograph chambers in 
volumes not greater than 0.02 ml. Drug concentrations are reported as final molar concentrations 
in the myograph chamber.  
Data Analysis:  Relaxation responses are expressed as a percent of the initial tension 
induced by 5-HT (10-7 M).  EC50 values (drug concentration that produced 50% of its own maximal 
response) were determined, converted to their negative logarithm, and expressed as -log molar 
EC50 (pD2). RT-qPCR data were analyzed to quantify relative gene expression by ΔCt relative to 
β-actin. For NO imaging, amplitude of DAF-2 fluorescence was calculated by subtracting peak 
fluorescence intensity from basal fluorescence intensity.  Results are expressed as means ± SEM, 
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and n refers to the number of animals from which blood vessels were taken, unless otherwise 
stated. Values were compared by Student’s t-test or one-way ANOVA using Tukey’s test as post-
hoc analysis for paired or unpaired observations, as appropriate, to determine significance between 
groups. Values were considered significantly different when p<0.05. 
Results 
APJ Receptor Expression and Localization 
APJ receptor expression was analyzed using RT-qPCR and immunoblot analyses. Both 
protein (Figure 15A) and mRNA transcripts (Figure 15B) suggest APJ receptor are expressed in 
coronary arteries along with rat lung tissue, which was used as a positive control (58). Moreover, 
APJ receptor protein was localized in both endothelial and smooth muscle cells of coronary artery 
(Figure 15C.1- C.3) using immunofluorescence confocal microscopy. Rat lung tissue was used to 
demonstrate staining for APJ receptors on bronchial epithelium (Positive control, Figure 15C.5); 
inset shows non-specific binding of the secondary antibody in the absence of primary antibody for 
APJ receptors. 
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Fig. 15. Expression and localization of APJ receptors.  
(A) Representative immunoblot showing expression of APJ receptor (APJR) protein in 
homogenates from rat coronary arteries (Lane 1) and lung tissue (Lane 2); β-actin was used as a 
loading control.  The immunoblots shown are representative of data obtained from five different 
animals.  (B) Bar graph showing relative mRNA expression of APJ receptor, represented as ΔCt 
values relative to β-actin. Data are presented as mean ± SEM (n=3). (C) Representative 
immunofluorescence images of: (1) APJ receptors (red fluorescence); (2) merged image showing 
endothelial cells (magenta fluorescence) with smooth muscle cells actin (green fluorescence); (3) 
merged image showing APJ receptor co-localized areas in smooth muscle cells (yellow 
fluorescence) and endothelium (red fluorescence) in rat coronary artery; (4) differential 
interference contrast image of rat coronary artery; and (5) APJ receptors (red fluorescence) with 
nuclear staining (blue fluorescence) in rat bronchial epithelium (positive control); inset 
demonstrates a lack of staining after incubation of tissue with serum followed by the secondary 
antibody (negative control). The images are representative of those obtained from three different 
animals. Scale bar, 20 μm.  
 
Vascular Relaxation Studies 
In coronary arteries contracted with 5-HT (10-7 M), increasing concentration of apelin (10-8 
– 3 x 10-6 M) caused endothelium dependent relaxation, which was blunted with endothelium 
denudation (% Emax: 44.74 ± 6.56 vs. 15.54 ± 3.73 with and without endothelium respectively, 
p<0.05) (Figure 16A). Similarly, an APJ receptor antagonist, F13A (10-7 M) abolished apelin-
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induced relaxations (Figure 16B), but had no effect on the response to acetylcholine (10-9 M – 3 
x 10-6 M) (Figure 16C).  
 
Fig. 16. Apelin causes endothelium APJ receptor dependent relaxation of isolated coronary 
arteries.  
(A) Representative original tracings of isometric tension recordings from isolated coronary arteries 
(with and without endothelium) in response to cumulative addition of increasing concentrations of 
apelin, followed by acetylcholine (ACh; 10-6 M) and diltiazem (10-5 M). Log concentration-
response curve for (B) apelin-induced relaxation in coronary arteries with endothelium (E+), which 
was abolished in the endothelium denuded (E-) segments or in the presence of F13A (10-7 M) and 
(C) acetylcholine in the absence and presence of F13A (10-7 M). Data are expressed as a percentage 
of the initial increase in tension induced by 5-HT (10-7 M).  Each point represents the mean ± 
S.E.M. (n=5-9). 
 
Experiments were then performed to evaluate the mediators involved in apelin-induced 
relaxation. Apelin-induced relaxations were significantly inhibited in the presence of the 
endothelial NO synthase inhibitor, NLA (3 x 10-5 M) (Figure 17A), whereas guanylyl cyclase 
inhibitor, ODQ (10-5 M) was without effect (% Emax: 37.04 ± 4.68 vs. 41.98 ± 6.90 without and 
with ODQ respectively, p>0.05) (Figure 17B). Likewise, protein kinase G inhibitor, DT-2 (10-6 
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M) and cyclooxygenase inhibitor, indomethacin caused no change in the response to apelin 
(Figure 17C and 17D).   
 
Fig. 17. Apelin-induced response in dependent on nitric oxide, but not on cGMP or Protein Kinase 
G. 
Log concentration-response curves for apelin in producing relaxation of endothelium-intact 
coronary arteries in the absence and presence of (A) nitro-l-arginine (NLA; 3 x 10-5 M, n=6); (B) 
ODQ (10-5 M, n=5); (C) DT-2 (10-6 M, n=6); and (D) indomethacin (10-5 M, n=6). Data are 
expressed as a percentage of the initial increase in tension induced by 5-HT. Each point represents 
the mean ± S.E.M.  
 
Vasoactive response of a known endothelium dependent vasodilator, acetylcholine (ACh) 
was also assessed in coronary arteries segments. ACh (10-9 M – 3 x 10-6 M)-induced relaxation 
was attenuated in the presence of NLA (% Emax: 97.24 ± 1.74 vs. 39.84 ± 10.44 without and with 
NLA respectively, p<0.05), and similarly by ODQ (10-5 M) or DT-2 (10-6 M) (Figure 18A-C). 
However, cyclooxygenase inhibitor, indomethacin (10-5 M) caused no change in apelin or ACh-
induced response (Figure 18D).  
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Fig. 18. NO-cGMP pathways in coronary arteries mediate acetylcholine-induced response.   
Log concentration responses for acetylcholine in the absence and presence of (A) NLA (3 x 10-5 
M, n=7); (B) ODQ (10-5 M, n=6); (C) DT-2 (10-6 M, n=6) and (D) indomethacin (10-5 M, n=7).  
Each point represents the mean ± S.E.M.  
 
The BKCa channel blocker, iberiotoxin (IBTx; 10
-7 M) inhibited apelin and acetylcholine-
induced relaxation (Figure 19A-B), whereas KATP channel blocker, glyburide (10
-6 M), was 
without effects (Figure 21A).  
 
Fig. 19. Apelin and acetylcholine-induced nitric oxide activates BKCa channels to relax coronary 
arteries.  
Log concentration-response curves for (A) apelin and (B) acetylcholine in producing relaxation of 
endothelium-intact coronary arteries in the absence and presence of iberiotoxin (10-7 M, n=6). 
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Role of BKCa channels in NO-induced relaxation was further evaluated in high potassium 
(40 mM K+) contracted arterial segments. Apelin-induced endothelium dependent relaxation was 
completely abolished in the segments contracted with 40 mM K+ (Figure 20A), whereas ACh 
response had a rightward shift with inhibition of maximum relaxation (% Emax: 98.6 ± 1.40 vs. 
75.50 ± 5.05 with 5-HT and 40 mM K+ contractions respectively, p<0.05) (Figure 20B). 
 
Fig. 20. Apelin-induced relaxation requires activation of smooth muscle K+ channels.  
Log concentration response curve for (A) apelin and (B) acetylcholine in producing relaxation of 
endothelium-intact coronary arteries contracted with 5-HT (10-7 M) and 40 mM K+. Each point 
represents the mean ± S.E.M. (n=7-11). 
 
Possible involvement of other pathways i.e. NO-induced activation of sarco/endoplasmic 
reticulum Ca²⁺-ATPase (SERCA) pump and hydrogen peroxide (H2O2) were evaluated using 
SERCA inhibitor, cyclopiazonic acid (CPA, 2 x 10-5 M) and a well-known decomposer of H2O2, 
PEG-Catalase (P-Catalase, 500 U/ml) respectively. The presence of CPA had no effect on apelin-
induced relaxations, whereas ACh-induced relaxation was inhibited (% Emax: 98.77 ± 1.22 vs. 
51.44 ± 5.08 without and with CPA respectively, p<0.05) (Figure 21B). Moreover, presence of P-
catalase had no effect on either apelin or ACh-induced relaxations (Figure 21C). 
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Fig. 21. Apelin-induced response is not dependent on KATP channels, SERCA and hydrogen 
peroxide.  
Bar graph representing maximum relaxation response of apelin (3 x 10-6 M) and acetylcholine 
(10-6 M) in endothelium-intact coronary arteries in the absence and presence of (A) glyburide (10-6 
M, n=6); (B) Cyclopiazonic acid (CPA, 2 x 10-5 M, n=6); and (C) PEG-catalase (P-catalase, 
500u/ml, n=5). Each point represents the mean ± S.E.M. *p<0.05 vs. ACh alone. 
 
Intracellular NO and Cyclic GMP Measurement 
In freshly isolated endothelial cells, apelin (10-7 M) increased DAF-2 fluorescence, which 
was inhibited in the presence of NLA (3 x 10-5 M) or F13A (10-7 M) (Figure 22A and 22B). 
Likewise, ACh (10-6 M) also increased DAF-2 fluorescence, which was abolished in the presence 
of NLA (3 x 10-5 M), whereas F13A (10-7 M) was without any effect (Figure 22C). 
Intracellular cGMP levels were measured by incubating freshly coronary arteries with 
apelin or ACh.  Different concentration of apelin caused no change in basal cGMP levels (Figure 
23A), but ACh (10-6 M) caused a marked increase in intracellular cGMP, which was inhibited in 
the presence of NLA (3 x 10-5 M) or ODQ (10-5 M) (Figure 23B). 
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Fig. 22. Apelin increases intracellular NO production, similar to acetylcholine.  
A) Representative images of DAF-2 (5 µM) loaded freshly isolated coronary ECs (1) before and 
(2) after apelin (10-7 M) treatment. Bar graph representing increase in DAF-2 fluorescence after 
exposure to (B) apelin (10-7 M) and (C) acetylcholine (10-6 M) in the absence and presence of NLA 
(3 x 10-5 M) or F13A (10-7 M). Amplitude of change in DAF fluorescence was calculated as the 
maximal fluorescence after agonist exposure corrected for baseline fluorescence.  Values are 
represented as means ± S.E.M. (n = 4 - 6 animals, 9 - 18 total cells). * p<0.05 vs. apelin or 
acetylcholine alone as calculated by ANOVA using Tukey’s test as post-hoc analysis.  
 
 
Fig. 23. Acetylcholine, but not apelin increases intracellular cGMP production in coronary arteries.  
Bar graph representing effect of (A) apelin and (B) acetylcholine (10-6 M) on intracellular cGMP 
levels in intact coronary arterial segments. Values are represented as means ± S.E.M. (n = 4). * p 
<0.05 vs. ACh; and # p<0.05 vs. basal. 
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Electrophysiology Studies 
Whole cell K+ currents were increased in the presence of exogenous NO - donor DEA 
NONOate (DEA; 10-5 M) (Figure 24A). The BKCa channel blocker, iberiotoxin (10
-7 M) 
attenuated basal and DEA- induced whole cell K+ currents (Figure 24G), whereas ODQ (10-5 M) 
had no inhibitory effects on basal and NO – donors induced current density (Figure 24A-F and 
25). 
 
Fig. 24. DEA NONOate-induced increase in whole cell BKCa currents were not inhibited by ODQ, 
but by iberiotoxin.   
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV before and after treatment with DEA NONOate (DEA, 10-5 M) with and without 
ODQ (10-5 M) or Iberiotoxin (IBTx, 10-7 M). A-D: Representative tracings depicting the sequential 
current recordings from a single smooth muscle cell (A and C) before and (B) after treatment of 
DEA (10-5 M, 2 min) alone or (D) in combined presence of ODQ (10-5 M, 5 min) and DEA (10-5 
M, 2 min); E-G: Summary I-V curve plots of BKCa currents at baseline and after treatment with 
DEA (10-5 M), in the (E) absence and (F) presence of ODQ (10-5 M); or (G) Iberiotoxin (IBTx; 10-
7 M). Values are represented as mean ± SEM (n=6). * p<0.05 vs. control current density. 
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Fig. 25. Sodium nitroprusside-induced increase in whole cell BKCa currents are not inhibited by 
ODQ. 
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV before and after treatment with sodium nitroprusside (SNP; 10-5 M) with and 
without ODQ (10-5 M). A-D: Representative tracings depicting the sequential current recordings 
from a single smooth muscle cell (A and B) before and (C) after treatment of SNP (10-5 M, 2 min) 
alone or (D) in combined presence of ODQ (10-5 M, 5 min) and SNP (10-5 M, 2 min); E-F: 
Summary I-V curve plots of BKCa currents at baseline and after treatment with SNP (10
-5 M), in 
the absence (E) and presence of (F) ODQ (10-5 M). Values are represented as mean ± SEM (n=6). 
*p<0.05 vs control current density. 
 
Discussion 
There are two novel findings in this study. First, data show that apelin by binding to 
endothelial APJ receptors can cause NO mediated relaxation that does not require cGMP-PKG as 
mediators, but direct activation of smooth muscle BKCa channels. Second, both apelin and 
acetylcholine activate eNOS to form nitric oxide or reactive nitrogen species (RNS, ex. 
peroxynitrile or nitrate), but induced relaxations are mediated by different downstream mediators. 
Our understanding about apelin-APJ axis in the regulation of vascular tone is continuously 
evolving, but the consensus is apelin causes nitric oxide dependent relaxation in the peripheral 
arteries.  Much of the data, which examines vasodilation mechanism(s) of apelin, are limited to 
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involvement of nitric oxide, however the downstream mediators activated by apelin-induced nitric 
oxide are yet to be identified. Endogenous nitric oxide can activate diverse signaling pathways in 
different vascular beds, but the ability of nitric oxide to activate multiple pathways in same blood 
vessel is unknown. To my knowledge, this is the first report providing novel evidence that apelin 
and acetylcholine-induced NO can relax vascular smooth muscle cells by different downstream 
mediators.  These results suggest possibilities of 1) nitric oxide itself can produce diverse response 
based on physiological stimuli i.e. apelin vs. acetylcholine; 2) eNOS activation generates multiple 
vasoactive RNS in coronary arteries to relax of vascular smooth muscle cells.  
In agreement with the previous reports, APJ receptor were localized in both endothelial 
and smooth muscle cells of rat coronary arteries (5, 18, 79). APJ receptors are uniformly distributed 
on endothelial cell lining, whereas has a punctate appearance on smooth muscle cells of arterial 
wall. In line with APJ receptor expression, apelin-induced endothelium dependent relaxation under 
physiological conditions (22, 38), but in contrast to previous reports, we did not observe 
vasoconstriction in endothelium denuded arterial segments (22, 67). The observed differences in 
endothelium independent response can be attributed different arterial preparations and contractile 
agents used during different studies. Apelin-induced relaxations were blocked by APJ receptor 
antagonist, F13A (11), confirming apelin selectively activates endothelial APJ receptors to 
produce relaxation of coronary arteries. 
Apelin increases human forearm blood flow via nitric oxide (52) and improves coronary 
blood flow and cardiac output in humans (76). Moreover, apelin decreases mean arterial pressure 
and produces protective vascular effects via endothelial nitric oxide (40, 43, 55, 75). In several 
isolated arterial preparations, apelin caused endothelium dependent relaxation, in part by nitric 
oxide dependent pathways (22, 38). Most of these studies have used endothelial nitric oxide 
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synthase (eNOS) inhibitor, nitro-L-arginine methyl ester (L-NAME) or other nitro-L-arginine 
analogs to decipher the role of nitric oxide. In agreement with previous results, eNOS inhibitor, 
NLA inhibited apelin-induced vascular response in endothelial intact coronary arteries, similar to 
a known endothelial nitric oxide dependent vasodilator, acetylcholine (119-121).   
Nitric oxide can activate various downstream mediators to relax vascular smooth muscle 
cells including cGMP by activating soluble guanylate cyclase (sGC) (116), SERCA to increase 
intracellular Ca2+ re-uptake (50), smooth muscle potassium channels like BKCa to cause 
hyperpolarization (48, 49). Interestingly, apelin-induced relaxation was not inhibited in the 
presence sGC inhibitor, ODQ or protein kinase G inhibitor, DT-2 suggesting cGMP and/or PKG 
are not involved in apelin-induced relaxation. By contrast, response to acetylcholine was inhibited 
in the presence of ODQ and DT-2. Moreover, apelin had no effect on basal cGMP levels, whereas 
acetylcholine increased intracellular cGMP formation, which was inhibited by NLA or ODQ. 
These results suggest that apelin and acetylcholine-induced NO (or RNS) can activate different 
mediators to relax vascular smooth muscle of coronary arteries. However, nitro-L-arginine has an 
ability to inhibit effects of hydrogen peroxide (122). The possible involvement of hydrogen 
peroxide was precluded by experiments in the presence of PEG-Catalase (123, 124), which had no 
effect on both apelin or acetylcholine-induced relaxations. The functional role of nitric oxide was 
further confirmed by real time intracellular NO imaging using DAF-2DA. Apelin increased DAF-
2DA fluorescence similar to acetylcholine, which was inhibited in the presence of NLA.  DAF-
2DA is widely used fluorometric tool to estimate intracellular nitric oxide levels, however its 
selectivity towards nitric oxide is still questionable. Previous reports suggest that DAF-2DA is 
more sensitive towards peroxynitrile than nitric oxide (125), and DAF fluorescence can be 
modulated in the presence of other reactive species and/or Ca2+ ions (126, 127). Although in the 
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present study, both apelin and acetylcholine-induced similar DAF fluorescence, the possible 
involvement of other RNS cannot be excluded (45). 
Based on the involvement of nitric oxide, my next hypothesis was that apelin-induced nitric 
oxide can relax coronary arteries by direct activation of BKCa channels (48, 49). In here, apelin-
induced relaxations were blocked by a selective and potent BKCa channel blocker, iberiotoxin. 
Likewise, acetylcholine-induced response was attenuated in the presence of iberiotoxin. Moreover, 
apelin-induced response was completely abolished in the presence of high K+-induced contractile 
tone, however acetylcholine-induced response had a rightward shift with inhibition of maximum 
relaxation, establishing disparity in the extent of K+ channels involvement in these two 
vasodilators-induced response. Additionally, NO donor - DEA NONOate increased whole cell K+ 
currents, which were markedly attenuated by IBTx, but not in the presence of ODQ, further 
supporting the possibilities that nitric oxide can directly activate BKCa channels to relax the 
coronary arteries. These data questions the similarity between exogenous and intracellular NO. 
The electrophysiology data suggest similarities in NO donor and apelin-induced nitric oxide 
response, but also identifies that acetylcholine-induced NO differs from the ones generated by 
exogenous donors (44).  
Moreover, apelin-induced relaxations were unchanged in presence of CPA, a potent 
SERCA inhibitor (128), provides further support for the view that apelin-induced NO can directly 
activate BKCa channels to relax coronary arteries. By contrast, CPA attenuated acetylcholine-
induced relaxation confirming the possibilities of different vasoactive pathways activated by nitric 
oxide in the response to different physiological stimulus.  
In summary, apelin and acetylcholine both cause endothelium nitric oxide dependent 
relaxation in coronary arteries by distinct mechanisms i.e. apelin-induced NO directly activates 
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BKCa channels, whereas acetylcholine increases NO-cGMP cascade to activate multiple pathways 
including BKCa channels and SERCA. These results indicate the possibilities of distinct 
physiological mechanism(s) involving nitric oxide activated in response to different vasodilators, 
to modulate the vascular tone of coronary arteries. This novel physiological response of apelin 
needs further evaluation in other vascular beds, to provide a comprehensive and advanced 
understanding about apelinergic system.   
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CHAPTER 4. EFFECT OF APELIN ON BKCa CHANNELS AND NITRIC 
OXIDE-INDUCED RELAXATION IN CORONARY ARTERIES: 
COMPARISON WITH CEREBRAL ARTERIES 
Introduction 
APJ receptor and its cognate ligand; apelin is continuously evaluated for their therapeutic 
potentials in cardiovascular regulation.  Role of apelin-APJ signaling in vasomotor tone regulation 
is defined by their higher expression on vascular walls (4, 5, 20) and cardiovascular regulatory 
region i.e. hypothalamus and brain stem (58, 78, 80). Interestingly, apelin has different effects in 
central and peripheral system (54). Apelin is classified as a vasodilator based on its ability to relax 
peripheral arteries including aorta (40, 129), mesenteric and mammary arteries (22, 38, 79).  
However, central administration or increased gene expression of apelin in hypothalamus and other 
regulatory regions of brain are shown to cause vasopressor response (59, 60). Likewise, response 
to central administered apelin on fluid homeostasis and metabolism also differs, as intraperitoneal 
administered apelin increases energy expenditure and water intake, but intracerebroventricular 
injection has opposite effects (19, 36, 130). However, effects of apelin on cerebral and peripheral 
vascular system are still unknown. Our recent report is the first one to propose that vasoactive 
action of apelin on cerebral arteries may not be protective, like peripheral arteries (30). My 
previous data suggest that apelin by inhibiting BKCa channels can impair endothelium nitric oxide 
dependent relaxation. BKCa channels are highly localized on smooth muscle cells and has essential 
modulating role in maintaining membrane potential and vasodilation (94, 95) and impairment of 
BKCa channel functions can result into cerebral vasospasm.  
Apelin is shown to have dual vascular effects in peripheral blood vessels as well, depending 
on underlying physiological or pathological conditions. Apelin causes endothelium dependent 
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vasodilation (38, 40, 43), but can also induce vasoconstriction in endothelium denuded or 
dysfunctional blood vessels (67, 79). It is important to note that this phenomenon is described in 
very limited vascular beds and in models with pathological conditions. Moreover, a limited amount 
of information is available about the possible mechanisms involved in apelin-induced 
vasoconstriction. The possible signaling events that are suggested to be involved include PKC 
dependent MLC phosphorylation (33, 67) and PI3K dependent inhibition of BKCa channels (30, 
81). 
Apelin has beneficial effects during ischemia reperfusion injury, myocardial infraction and 
heart failure (13, 76). However, higher expression of apelin in atherosclerotic plaques (18) and 
stenosis valve disease (71) has been associated with the progression of disease. Surprisingly, 
regulatory fuctions of apelin-APJ signaling in coronary arteries are not studied thus far. A well-
defined role of coronary arteries in cardiovascular system and increasing evidence-supporting role 
of apelin in coronary blood flow (52, 76) warrants a careful examination of apelin-induced vascular 
effects in coronary arteries smooth muscle cells. Hence, the present study has two specific aims: 
1. determine functional role of apelin-APJ signaling in coronary arterial smooth muscle cells; and 
2. compare the signaling events activated in response to apelin between coronary and cerebral 
arteries. 
Materials and Methods 
Animals and Tissue Preparation:  Experiments were performed on tissues isolated from 
12-week-old male Sprague-Dawley rats (Envigo RMS, Indianapolis, IN).  Rats were housed at 22 
± 2°C on a 12 h-12 h light-dark cycle and provided with food and water ad libitum. All animal 
protocols were approved by the North Dakota State University Institutional Animal Care and Use 
Committee. Rat hearts and brains were isolated from animals anesthetized with isoflurane and 
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placed into ice-cold physiological salt solution (PSS). Epicardial coronary and cerebral arteries 
were dissected and cleaned of surrounding tissues.  
Smooth Muscle Cell Isolation:  Enzymatic isolation of single vascular smooth muscle 
cells was carried out as described previously, with brief modification (Gonzales et al., 2010). 
Arteries were placed in cell isolation solution of the following composition (in mM): 60 NaCl, 80 
Na-glutamate, 5 KCl, 2 MgCl2, 10 glucose, and 10 HEPES (pH 7.2). Arterial segments were 
initially incubated in 1.2 mg/ml papain (Worthington, Lakewood, NJ) and 2.0 mg/ml 
dithioerythritol (Sigma Aldrich, St. Louis, MO) for 17 min at 37°C and then in 0.8 mg/ml type II 
collagenase (Worthington) for 12 min at 37°C. The digested segments were washed three times in 
ice-cold cell isolation solution and incubated on ice for 30 min. After this incubation period, 
vessels were triturated to liberate smooth muscle cells and stored in ice-cold cell isolation solution 
for use. Smooth muscle cells were used for electrophysiology or imaging within 6 h following 
isolation. 
Electrophysiological Recording:  Isolated smooth muscle cells were placed into a 
recording chamber (Warner Instruments, Hamden, CT) and allowed to adhere for 20 min at room 
temperature. Whole cell currents were recorded using an AxoPatch 200B amplifier equipped with 
an Axon CV 203BU headstage (Molecular Devices). Current data were collected and analyzed 
with pCLAMP 10.0 software (Molecular Devices, Sunnywale, CA). The patch electrodes (3-4 
MΩ) were fabricated from 1.5-mm borosilicate glass capillaries. Smooth muscle cells were 
superfused at a rate of 2.0 ml/min with a solution containing (in mM) 145 NaCl, 5.4 KCl, 1.8 
CaCl2, 1 MgCl2, 5 HEPES, 10 glucose; pH 7.4 (NaOH).  Patch pipettes were filled with internal 
pipette solution contained (in mM) 145 KCl, 5 NaCl, 0.37 CaCl2, 2 MgCl2, 10 HEPES, 1 EGTA, 
7.5 Glucose; pH 7.2 (KOH). All drugs were diluted in fresh bath solution and perfused into the 
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experimental chamber. Voltage-activated currents were filtered at 2 kHz and digitized at 10 kHz, 
and capacitative and leakage currents were subtracted digitally. Series resistance and total cell 
capacitance were calculated from uncompensated capacitive transients in response to 10 ms 
hyperpolarizing step pulses (5 mV), or obtained by adjusting series resistance and whole-cell 
capacitance using the Axopatch 200B amplifier control system. Standard recording conditions for 
BKCa were achieved by stepping in 10 mV increments from a holding potential of -60 to +80 mV. 
BKCa currents were expressed as current density (current divided by its capacitance). 
Intracellular Ca2+ Imaging:  Smooth muscle cells were plated in eight-well borosilicate 
cover-glass chambers (ThermoFisher Scientific) and incubated for 60 min in 5 μM fluo-4 AM 
(ThermoFisher Scientific), washed, and perfused with HBSS. The real time imaging was 
performed using an Olympus confocal laser-scanning microscope (Olympus, Tokyo, Japan) with 
a 40x numerical aperture oil immersion lens (with excitation at 488 nm and emission at 515 nm). 
All experiments were carried out at room temperature in HBSS. The effect of various agonists and 
inhibitors on intracellular Ca2+ level was obtained in paired experiments. In experiments with 
inhibitor, F13A (10 7 M) was added to the chamber for 5 min before addition of apelin (10-7 M). 
Smooth muscle cells were isolated from four animals (each animal on different day) and 2-3 cells 
were analyzed for each treatment from each animal. 
Vascular Function Studies:  Arterial rings (Cerebral: 80-100 µm and Coronary: 120-150 
µm; 1.2 mm in length) were suspended in wire myographs (DMT, Aarhus, Denmark) for isometric 
tension recording. The myograph chambers were filled with PSS (5 ml), which was continuously 
aerated with 95% O2/5% CO2 and maintained at 37°C throughout the experiment. Cerebral 
arteries were stretched and normalized as described previously (Chapter 2). Coronary arteries were 
stretched to using DMT normalization guide and then allowed to stabilize for 30-40 min with 
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intermittent washings as described previously (chapter 3). Vessel reactivity was confirmed by 
evoking a response to KCl (60 mM). In some vessels, the endothelium was removed by gently 
rubbing the intimal surface with a human hair. The presence or absence of endothelium was 
confirmed by measuring relaxation in response to the endothelium-dependent vasodilators, 
acetylcholine (10-6 M) and bradykinin (10-7 M) in coronary and cerebral arteries respectively.  
Responses to the vasodilators used in this study were obtained in arterial rings contracted with 5-
HT (10-7 M). Inhibitors were added to the myograph chamber 20 min prior to contraction with 5-
HT and the inhibitors remained in contact with the tissues for the remainder of the experiment.  
Experiments with inhibitors were conducted in parallel with control rings taken from the same 
animal. 
RT-qPCR:  Freshly isolated arteries were immediately frozen in liquid nitrogen to collect 
arterial lysate. Arterial and primary cultured endothelial cell total RNA were isolated using an 
RNeasy Mini kit, according to the manufacturer’s protocol (Qiagen, Germantown, MD). The 
concentration and purity of RNA was determined using a spectrophotometer (Nanodrop 
Technologies, Wilmington, DE). cDNA was synthesized using 50 ng of RNA and an iScript cDNA 
synthesis kit (Bio-Rad). A Sybr Green expression assay was used to determine expression of 
apelin, with β-actin used as a housekeeping gene (Bio-Rad). The following primers (synthesized 
by Invitrogen, Carlsbad, CA) were used: 
Apelin gene – forward: 5’-GAGGAAATTTCGCAGACAGC-3’; reverse: 5’-
CAGCGATAACAGGTGCAAGA -3’; β-actin – forward: 5’-GTCGTACCACTGGCATTGTG-
3’; reverse: 5’-TCTCAGCTGTGGTGGTGAAG-3’.  Real-time RT-PCR reaction conditions 
were 95°C for 10 min, followed by 40 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 30 s. 
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Immunofluorescence Microscopy:  Freshly isolated coronary and cerebral arteries were 
fixed in 10% formalin solution, processed and embedded in paraffin blocks. Paraffin blocks were 
sectioned at 5 μm and mounted onto ProbeOn Plus microscopic slides (ThermoFisher Scientific). 
Sections were fixed by heating at 60°C for 30 min. Nonspecific antibody binding was blocked 
with normal serum [10% w/v; in TBS] for 1 h at room temperature. Sections were incubated 
overnight at 4°C in 1% serum containing a primary antibody against apelin (Abcam, Cambridge, 
MA), smooth muscle actin (Santa Cruz Biotechnology) and/or PECAM-1 (Santa Cruz 
Biotechnology). For co-localization, double immunofluorescent staining was performed by 
incubating the tissue sections with more than one primary antibody at the same time. Detection of 
the primary antibodies against the apelin, smooth muscle actin and PECAM-1 was accomplished 
using Alexa Fluo-633 conjugated (donkey anti-rabbit IgG; Invitrogen, Carlsbad, CA), Alexa 
Fluor-488 (donkey anti-mouse IgG; Santa Cruz Biotechnology) and Alexa Fluor-555 (donkey anti-
goat IgG; Santa Cruz Biotechnology) secondary antibodies, respectively. Rat lung tissue was used 
as positive control for apelin detection (Hosoya et al., 2000).  All negative controls were incubated 
with 1% serum solution overnight followed by secondary antibodies. All dilutions and thorough 
washes between stages were performed using TBS containing Triton X-100 [0.3% (v/v)] unless 
otherwise stated.  Sections were drained by blotting with filter paper, and a drop of mounting 
medium containing an anti-fade reagent (Vector Laboratories, Burlingame, CA) was added to the 
slides. Images of the sections were obtained using an Olympus confocal laser-scanning microscope 
(Olympus, Tokyo, Japan). The images were generated using Olympus FluoView FV300 (v. 4.3) 
confocal software. 
Western Immunoblotting:  Freshly isolated coronary and cerebral arteries were 
immediately frozen in liquid nitrogen. Tissues were homogenized in lysis buffer and supplemented 
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with a protease and phosphatase inhibitor cocktail (FabGennix International, Frisco, TX) at 4°C 
using an IKA Ultra-Turrax T8 homogenizer (IKA Works Inc., Wilmington, NC). Tissue 
homogenates were kept on ice for 10 min and then centrifuged at 10000g for 10 min. Supernatant 
was collected, and protein determination was performed using a Pierce BCA protein estimation kit 
(ThermoFisher Scientific, Waltham, MA). Aliquots of supernatant containing equal amounts of 
protein (40 μg) were separated on 7.5-10% polyacrylamide gel by SDS polyacrylamide gel 
electrophoresis, and proteins were electroblotted onto a polyvinylidene difluoride membrane (Bio-
Rad Laboratories, Hercules, CA). Blots were blocked with 5% nonfat dry milk in Tris-buffered 
saline (TBS, pH 7.4) and incubated overnight at 4°C with a primary antibodies specific for Akt 
and phosphor-Akt using a dilution of (1:500) (Cell Signaling, Denver, MA). Membranes were 
washed three times for 10 min using TBS-Tween 20 and incubated with a horseradish peroxidase-
linked secondary antibody (Cell Signaling). To ensure equal loading, the blots were analyzed for 
β-actin expression using an anti-actin antibody (Santa Cruz Biotechnology Inc.). Immuno-
detection was performed using an enhanced chemiluminescence light detection kit (ThermoFisher 
Scientific). 
Drugs:  The following drugs were used: acetylcholine, diethylamine NONOate (DEA 
NONOate), sodium nitroprusside (SNP), diltiazem, 5-hydroxytryptamine (5-HT) and forskolin 
(Sigma Chemical, St. Louis, MO); iberiotoxin (Tocris, Ellisville, MO); apelin-13, and F13A (H-
Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH trifluoroacetate salt) (Bachem, 
Torrance, CA).  Drug solutions were prepared fresh daily, kept on ice, and protected from light 
until used. All drugs were dissolved in double-distilled water with the exception of forskolin, 
which was dissolved initially in DMSO prior to further dilution in double-distilled water. Drugs 
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were added to the myograph chambers in volumes not greater than 0.02 ml. Drug concentrations 
are reported as final molar concentrations in the myograph chamber. 
Data Analysis:  Relaxation responses are expressed as a percent of the initial tension 
induced by 5-HT (10-7 M).  EC50 values (drug concentration that produced 50% of its own 
maximal response) were determined, converted to their negative logarithm, and expressed as -log 
molar EC50 (pD2). For Ca2+ imaging, amplitude of DAF-2 fluorescence was calculated by 
subtracting peak fluorescence intensity from basal fluorescence intensity. RT-qPCR data were 
analyzed to quantify relative gene expression by ΔCt relative to β-actin. Results are expressed as 
means ± SEM, and n refers to the number of animals from which blood vessels were taken, unless 
otherwise stated. Values were compared by Student’s t-test or one-way ANOVA using Tukey’s 
test as post-hoc analysis for paired or unpaired observations, as appropriate, to determine 
significance between groups. Values were considered significantly different when p<0.05. 
Results 
Electrophysiology Studies 
Whole cell BKCa currents were recorded in freshly isolated smooth muscle cells from 
coronary and cerebral arteries. In cells isolated from coronary arteries, super perfusion of apelin 
(10-7 M, 5 min) had no inhibitory effects of BKCa channel current density, but further addition of 
iberiotoxin; (IBTx, 10-7 M, 5 min) caused a significant reduction in current density (Figure 26A 
and 26B). Likewise, DEA NONOate (DEA, 10-5 M, 3 min) (Figure 24E) and NS1619 (10-5 M, 3 
min) (Figure 27B)-induced currents were not attenuated in the presence of apelin (Figure 26C 
and 27C), but were significantly inhibited by IBTx (Figure 26D and 27D) in coronary arterial 
smooth muscle cells. In contrast, apelin (10-7 M, 5 min) caused a significant reduction in BKCa 
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channel current density, in cerebral smooth muscle cells, induced by membrane depolarization 
(Figure 28) or DEA (Figure 11). 
 
Fig. 26. Apelin does not inhibit BKCa channels currents in coronary arterial smooth muscle cells. 
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV with and without apelin (10-7 M) and/or Iberiotoxin (IBTx, 10-7 M). A.I - IV: 
Representative tracings depicting the sequential current recordings from a single smooth muscle 
cell I) control, in the presence of (II) apelin (10-7 M, 5 min) alone or (III) combined with IBTx 
(10-7 M, 5 min) and (IV) Wash; B-D: Summary I-V curve plots of BKCa currents at baseline (B) 
and after treatment with DEA (10-5 M), in the presence of (C) apelin and (D) IBTx (10-7 M). Values 
are represented as mean ± SEM (n=6). * p<0.05 vs. control current density. 
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Fig. 27. Apelin has no inhibitory effects on BKCa channel currents-induced by NS1619. 
Whole cell BKCa currents were recorded in freshly isolated vascular smooth muscle cells in 
response to successive voltage pulses of 800 ms duration, increasing in 10 mV increments from -
60 mV to +80 mV with and without apelin (10-5 M) and/or Iberiotoxin (IBTx, 10-7 M). A (I – III): 
Representative tracings depicting the sequential current recordings from a single smooth muscle 
cell I) control, in the presence of (II) apelin (10-7 M, 5 min) alone and (III) along with NS1619 
(10-5 M, 3 min); B - D: Summary I-V curve plots of BKCa currents at (B) baseline and after 
treatment with NS1619 (10-5 M), in the presence of (C) apelin (10-7 M) and (D) IBTx (10-7 M). 
Values are represented as mean ± SEM (n=6). * p<0.05 vs. control current density. 
 
 
Fig. 28. Apelin inhibits BKCa channels currents in cerebral arterial smooth muscle cells. 
Summary I-V curve plots of BKCa currents at baseline and in the presence of (A) apelin (10
-7 M) 
and (B) IBTx (10-7 M) in cerebral arterial smooth muscle cells. Values are represented as mean ± 
SEM (n=6-7). * p<0.05 vs. control current density. 
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Functionality of APJ receptor 
Intracellular calcium imaging was used to determine functionality of coronary and cerebral 
smooth muscle APJ receptor.  Freshly isolated smooth muscle cells were stimulated with different 
concentrations of apelin (10-7 M and 10-6 M). Apelin (10-7 M) caused a strong rapid and transient 
signal in smooth muscle cells, isolated from both coronary and cerebral arteries, and fluorescent 
intensity was not affected by further increasing apelin concentration to 10-6 M. Likewise, bolus 
addition of apelin (10-6 M) caused an increase in fluorescence intensity. APJ receptor antagonist, 
F13A (10-7 M, 5 min) completely abolished apelin-induced increase in intensity; however, F13A 
by itself had no effect (Figure 29). 
 
Fig. 29. Smooth muscle APJ receptor are functionally active. 
(A) Representative images of Fluo-4 AM (1 µM) loaded freshly isolated smooth muscle cells (1) 
before and (2) after treatment of apelin (10-7 M). Bar graph representing increase in Fluo-4 AM 
fluorescence after exposure to apelin (10-7 M or 10-6 M) in the absence and presence of F13A (10-7 
M) in (B) cerebral arterial and (C) coronary arterial smooth muscle cells. Amplitude of change in 
Fluo-4 AM fluorescence was calculated as the maximal fluorescence after agonist exposure 
corrected for baseline fluorescence.  Values are represented as means ± S.E.M. (n = 4 animals, 5 - 
15 total cells). * p<0.05 vs. apelin 10-7 M and #  p<0.05 vs. apelin 10-6 M as calculated by paired t-
test.  
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Vascular Relaxation Studies 
In coronary arterial segments contracted with 5-HT (10-7 M), nitric oxide donors DEA 
NONOate (DEA, 10-9 - 3 x 10-5 M) and sodium nitroprusside (SNP, 10-9 - 3 x 10-5 M) caused 
concentration dependent relaxations.  Apelin (10-7 M) had no inhibitory effect on DEA (6.38 ± 
0.20 vs. 6.15 ± 0.28 without and with apelin, n=5) and SNP (7.69 ± 0.15 vs.7.43 ± 0.27 without 
and with apelin, n=5)-induced relaxations (Figure 30A and 30C), but IBTx caused a marked 
inhibition (Figure 30B and 30D). Similarly, acetylcholine induced nitric oxide-cGMP dependent 
relaxation (Figure 18A-B), was attenuated by IBTx, but apelin was without effect (pD2: 7.16 ± 
0.17 vs. 7.38 ± 0.30, p>0.05, n=6) (Figure 31A-B). 
 
Fig. 30. Apelin does not inhibit nitric oxide donors-induced relaxations of coronary arteries. 
Log concentration-response curve for DEA NONOate (A and C) and Sodium nitroprusside (B and 
D) in producing relaxation of endothelium denuded coronary arteries in the absence and presence 
of apelin (10-7 M) or IBTx (10-7 M).  Values are represented as mean ± SEM (n=4-6). 
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Then experiments were performed to evaluate effects of apelin on contractile response 
curve of 5-HT (10-9 - 3 x 10-5 M).  In endothelium intact coronary arterial segments, apelin had no 
effect of contractile tone induced by 5-HT. However, apelin (10-7 M) caused a significantly 
leftward shift in the response to 5-HT in endothelium denuded arterial segments (pD2: 7.16 ± 0.17 
vs. 7.38 ± 0.30, p>0.05, n=6) with no significant change in maximum contractile response (Figure 
31C-D). However, apelin had no effect on 5-HT -induced contractile response in cerebral arteries 
segments with or without endothelium. 
 
Fig. 31. Apelin does not impair acetylcholine-induced relaxation, but exacerbate 5-HT contractile 
response. 
Log concentration-response curve for A-B) acetylcholine in producing relaxation of endothelium 
intact coronary arteries in the absence and presence of (A) apelin (10-7 M) or (B) IBTx (10-7 M); 
(C-D) 5-HT in producing vasoconstriction of endothelium (C) intact and (D) denuded coronary 
arteries in the absence and presence of apelin (10-7 M). Values are represented as mean ± SEM 
(n=6). 
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Effect of apelin on cAMP-induced response was evaluated using an adenylate cyclase 
activator, forskolin. Apelin had no inhibitory effects on forskolin (10-9 - 3 x 10-5 M)-induced 
concentration dependent relaxation of coronary arteries (pD2: 7.08 ± 0.31 vs. 7.12 ± 0.32 without 
and with apelin, n=6), but caused a rightward shift in the response in cerebral arteries (pD2:  6.94 
± 0.17 vs. 6.28 ± 0.15 without and with apelin, n=5), which was abolished in the presence of F13A 
(Figure 32). 
 
Fig. 32. Apelin impairs forskolin-induced relaxation of cerebral, but not of coronary arteries. 
Log concentration-response curve for forskolin in producing relaxation of endothelium denuded 
(A) coronary, and cerebral arteries in the absence and presence of (B) apelin (10-7 M) alone; or (C) 
with F13A (10-7 M). Values are represented as mean ± SEM (n=5-6). 
 
Expression of Apelin 
RT-qPCR and immunofluorescence confocal microscopy were used to determine 
expression and localization of apelin gene transcripts and protein respectively. Figure 33A shows 
expression of apelin gene transcript in coronary and cerebral arteries in comparison to rat lung 
tissue, which was used as a positive control (17). Likewise, apelin transcripts levels were also 
similar in primary endothelial cells cultured from coronary and cerebral arteries (Figure 33B). 
Immunofluorescence staining showed localization of apelin in endothelial in both cerebral and 
coronary arteries (Figure 33C). Moreover, apelin protein was also localized in smooth muscle in 
coronary arteries. Rat lung tissue demonstrated selective binding of apelin antibody on bronchial 
epithelium (Figure 33C.7); inset showed non-specific binding of secondary antibody by itself. 
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Fig. 33. Expression and localization of apelin. 
Bar graph showing relative mRNA expression of apelin, represented as ΔCt values relative to β-
actin in A) intact cerebral and coronary arteries and (B) primary endothelial cells cultured from 
cerebral and coronary arteries. Data are presented as mean ± SEM (n=4-6). (C) Representative 
immunofluorescence images of: 1 and 4: apelin (red fluorescence); 2 and 5: merged image showing 
endothelial cells (magenta fluorescence) with smooth muscle cells actin (green fluorescence); 3 
and 6: merged image showing apelin co-localized areas in smooth muscle cells (yellow 
fluorescence) and endothelium (red fluorescence) in rat coronary artery (top panel) and cerebral 
artery (middle panel); and 7: apelin (red fluorescence) with nuclear staining (blue fluorescence) in 
rat bronchial epithelium (positive control); inset demonstrates a lack of staining after incubation 
of tissue with serum followed by the secondary antibody (negative control). The images are 
representative of those obtained from four different animals. Scale bar, 20 μm. 
 
Effect of Apelin on PI3K/Akt Signaling Pathway 
PI3K activity was detected by the ratio of phosphorylated Akt and total Akt using western 
blot in coronary and cerebral arteries. Apelin (10-7 M) treatment had no significant effect on PI3K 
activity in coronary arteries, as indicated by unchanged p-Akt/total Akt ratio (Figure 34A-B). In 
cerebral arteries, apelin treatment stimulated time dependent increase in p-Akt level, which peaked 
at ~10 minute, indicating a two-fold increase in PI3K activity (Figure 34C-D). These data suggest 
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that PI3K pathways are activated in response to apelin in cerebral arteries, but not in coronary 
arteries. 
 
Fig. 34. Effect of apelin on PI3-kinase activity in coronary and cerebral arteries. 
Phosphorylated and total Akt levels were measured in coronary (A-B) and cerebral (C-D) arteries 
after treatment with apelin (10-7 M) for durations indicated in the figure. A and C: representative 
blots were probed with anti-serine-phosphorylation of Akt (p-Akt) or anti-Akt (total) antibodies 
along with β-actin. B and D: Bar graphs summarizing the effect of apelin on PI3-kinase activity 
expressed as a ratio of p-Akt/Akt protein levels. Data are means ± SEM (n=4). * p<0.05 compared 
with non-stimulated control. 
 
Discussion 
The major findings of the present study are: 1) apelin does not inhibit BKCa currents and 
nitric oxide dependent relaxation of coronary arteries; and 2) functionally active smooth muscle 
APJ receptor participates in different signaling pathways between cerebral and coronary arteries 
to regulate vasomotor tone. These findings provide novel information about functional differences 
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in apelinergic signaling between cerebral and coronary arteries, which can help us in designing 
targeted apelin based therapeutics to enhance beneficial effects, while reducing the associated risk. 
Vasoconstriction is known to be regulated by calcium release (63), MLC phosphorylation 
(64) and ion channels (65). APJ receptors are abundantly localized on vascular smooth muscle 
cells (30) and can cause vasoconstriction by modulating proteins (33) as well as ion channels (30). 
My previous data suggest that apelin alters vasomotor tone of cerebral arteries by impairing BKCa 
channel functions. Potassium ion channels are highly expressed throughout the vasculature 
including coronary arteries and are potential modulators for vessel diameter and reactivity. Hence, 
my first aim was to understand effect of apelin on BKCa channel currents in freshly isolated smooth 
muscle cells from coronary arteries. Surprisingly, apelin had no inhibitory effects on BKCa channel 
currents induced by membrane depolarization or by activators like nitric oxide donor or BKCa 
channel opener. However, IBTx caused significant inhibition of BKCa channel currents in the 
similar preparations. To further confirm these results using functional studies, effect of apelin was 
evaluated on exogenous and endogenous NO-induced relaxations and in line with the 
electrophysiology data, apelin had no inhibitory effects on NO-induced relaxation in coronary 
arteries. 
These findings raised questions about functionality of APJ receptor and signaling events 
activated by apelin-APJ receptor in coronary arteries. Functionality of APJ receptor was evaluated 
using non-ratiometric analysis with intracellular calcium indicator dye, Fluo-4 AM. Apelin 
treatment caused a substantial increase in fluorescence intensity, which was abolished in the 
presence of F13A, confirming smooth muscle APJ receptor of coronary arteries are functionally 
active. APJ receptor are shown to be coupled with multiple G-protein subunits (32-34) and 
previous data showed involvement of pertussis toxin sensitive Gαi/o subunits involvement in apelin-
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induced inhibitory effects on BKCa channels (30). Further, apelin is also shown to inhibit forskolin-
induced cAMP formation via pertussis toxin sensitive Gαi/o subunits (131). In present study, I 
determined effect of apelin on forsokin-induced relaxation of coronary and cerebral arteries. In 
line with previous results (30), apelin inhibited forskolin-induced response in cerebral arteries, but 
not in coronary arteries. 
Apelin-induced effects on vascular smooth muscle cells, including BKCa channel 
inhibition, are shown to be mediated by PI3K/Akt signaling pathways (30, 132, 133). Hence, I also 
evaluated effects of apelin on PI3K/Akt signaling pathways. The present results show that apelin 
has no effect on PI3K activity in coronary arteries, but significantly increases PI3K activity in 
cerebral arteries. These results altogether suggest activation of different signaling pathways in 
response to apelin between coronary and cerebral arteries. Further, I also determined expression 
and localization of apelin and in both cerebral and coronary arteries, apelin gene expression and 
localization were found similar as reported previously (17, 18, 78).   
Interestingly, apelin-induced vasoconstriction response in aorta is shown to be mediated 
by PKC and MLC phosphorylation (64, 67). Although, I did not observe any inhibitory effects of 
apelin on BKCa channel functions and nitric oxide dependent relaxations, but intriguingly apelin 
enhanced 5-HT-induced contractile response of endothelial denuded coronary arteries, and this 
effect of apelin was absent in endothelium intact arterial segment or in cerebral arteries. A 
significant role of MLC phosphorylation and intracellular calcium has been shown in 5-HT 
induced contractile response in coronary arteries (134, 135). It is possible that apelin exacerbate 
5-HT-induced contractile response by additive actions on MLC phosphorylation. Further studies 
in this direction can help in providing a comprehensive answer for the observed differences in 
apelin-induced response between cerebral and coronary arteries.  
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In summary, the present study suggests that apelin has different effects on smooth muscle 
BKCa channels between cerebral and coronary arteries. However, to provide a broader overview 
about effect of apelin in peripheral vasculature, further studies are required in other peripheral 
vascular beds, particularly in vascular beds where apelin is shown to increase PI3K/Akt activity 
(132, 133). Current findings along with others can help in developing apelin analogs with selective 
actions towards peripheral vasculature to produce beneficial cardiovascular response. 
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CHAPTER 5. SUMMARY AND CONCLUSIONS 
Targeting apelinergic system for cardiovascular diseases provides many exciting 
opportunities. Apelin-APJ receptor signaling has beneficial effects in many cardiovascular and 
metabolic diseases including hypertension, myocardial infraction-reperfusion injury, pulmonary 
hypertension, obesity and diabetes. However, a cautionary evaluation of controversial reports, 
about different vasoactive response of apelin, is prerequisite. Rather than focusing on peripheral 
beneficial effects, a broader overview of apelin signaling in different vascular beds can help us in 
better understanding diverse response of apelin. The complex apelin-APJ receptor signaling makes 
apelinergic system a challenging target for therapeutic development; however, the enormous 
potential of apelin along with various novel beneficial effects demand for a thorough 
understanding about apelin-induced effects. Current literature provides several key, but incomplete 
information about apelin-signaling such as: 1) apelin has different effects on cerebral and 
peripheral system, but vascular effects are not studied thus far; 2) apelin is shown to have beneficial 
vascular effects in peripheral arteries, but these conclusions are made based on data from limited 
vascular beds. Moreover, the mediators and signaling cascade(s) involved in apelin-induced 
vasodilation are not yet determined; and 3) possible pathways or signaling events involved in the 
different effects of apelin between central and peripheral vasculature (if any) are not studied thus 
far. 
Apelin and its analogs are currently being evaluated in multiple clinical trials for their 
therapeutic potential in pulmonary hypertension, myocardial infraction and coronary 
atherosclerotic heart disease (https://clinicaltrials.gov). Continuous efforts are made to design 
apelin analogs, but we still lack a comprehensive understanding about apelin signaling. Thus, the 
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present research was focused to determine apelin-induced vascular effects in cerebral arteries and 
compare them with coronary arteries. 
The results of the present study for the first time demonstrate the presence of APJ receptor 
gene transcripts and protein in cerebral and coronary arteries. Immunofluorescence imaging show 
that APJ receptors are localized on both endothelial and smooth muscle cells of cerebral arteries 
and coronary arteries. Moreover, apelin itself has no effect on vasomotor tone of cerebral arteries.  
However, apelin inhibits NO-induced relaxation in cerebral arteries by inhibiting BKCa channels 
functions.  BKCa channels are ubiquitously express on vascular smooth muscle cells and have an 
essential role in regulating membrane potential and hence, the vascular tone. BKCa channels are 
sensitive towards membrane depolarization and changes in intracellular calcium ion concentration. 
Activation of BKCa channels results into efflux of K
+ ions, bringing in hyperpolarization and 
vasorelaxation.  BKCa channels are regulated by multiple factors including intracellular calcium, 
phosphorylation and oxidation state, and dysregulation of BKCa channel function is correlated with 
increased risk of vasospasm and ischemia. Hence, these findings raise a potential concern about 
risk of cerebral vascular dysfunction under conditions where plasma levels of apelin are elevated, 
such as diabetes or obesity. 
Further, I evaluated vascular effects of apelin in coronary arteries and compared them with 
cerebral arteries. Interestingly, apelin causes endothelium dependent relaxation of coronary 
arteries and does not inhibit BKCa channel currents or functions in coronary arteries. Interestingly, 
functionally active smooth muscle APJ receptors are found to be participating in different signaling 
pathways between cerebral and coronary arteries. In cerebral arteries, apelin inhibits forskolin-
induced cAMP mediated relaxation and results into an increase PI3K activity. In contrast, apelin 
has no inhibitory effect on forskolin response and/or PI3K activity in coronary arteries. These 
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heterogeneities in vascular effects of apelin between cerebral and coronary arteries provide novel 
mechanistic details, which can be utilized in designing apelin-based therapies.  
Interestingly, apelin-induced relaxation of coronary arteries also has several novel and 
characteristic features: 1) apelin requires nitric oxide, but not cGMP to induce relaxation of 
coronary arteries; and (2) nitric oxide released in response to apelin can directly activate BKCa 
channels to mediate relaxation. Surprisingly, my results also suggest that nitric oxide generated in 
response to different stimuli (apelin vs. acetylcholine) has an ability to activate different signaling 
pathways. My data suggest that in contrast to apelin, acetylcholine causes relaxation via NO-
cGMP-PKG dependent pathways in coronary arteries. This phenomenon may provide a paradigm 
shift as current literature suggest that nitric oxide can activate different signaling pathways in 
different vascular beds. However, for the first time, I am reporting that nitric oxide can participate 
in multiple signaling pathways in a single vascular bed. 
The present research provides several new challenges and future directions. A logical 
extension would be to understand effects of endogenously released apelin on BKCa channel 
functions. Regulation and release of apelin in the circulation or surrounding tissue(s) are yet to be 
determined. It would be interesting to stimulate endogenous apelin release and evaluate its role in 
physiology and pathophysiology. My preliminary results in primary cultured cells isolated from 
cerebral arteries suggest that hypoxia causes time dependent increase in apelin gene expression, in 
both endothelial and smooth muscle cells (Figure 35). Nevertheless, whether this increased gene 
expression correlates with increase in apelin release has yet to be determined. In addition, it is 
essential to understand impact of apelin-induced inhibitory effects in pathological conditions like 
hypertension, diabetes and obesity with higher plasma apelin levels. Moreover, determination of 
these inhibitory actions of apelin in human cerebral arteries can not only advance our knowledge, 
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but also help in devising apelin-based therapy. Another novel feature of present study that has high 
impact in future research; understands possible reasons for differences in nitric oxide response 
with different stimulus. A guanylate cyclase knockout animal model can be utilized to further 
characterize the phenomenon. Likewise, analysis of possible signaling mechanisms-activated in 
response to apelin in coronary arterial smooth muscle cells can provide a comprehensive 
understanding about heterogeneous effects between cerebral and coronary arteries. The present 
research also suggest the possibilities that multiple subtypes of APJ receptor exists in mammals. 
In fact, a recent study showed that response of apelin analog is not dependent on APJ receptor, 
giving possibilities of another cell surface receptor having affinity towards apelin and its analogs. 
Future research to answer these puzzling questions can provide better opportunities to target 
beneficial effects of apelin in human physiology and cardiovascular diseases. 
 
Fig. 35. Effect of hypoxia on apelin gene expression in primary cultured cells from cerebral 
arteries. 
Bar graph representing fold change in apelin mRNA levels with the treatment of hypoxia (1% O2) 
in primary cultured (A) endothelial cells; and (B) smooth muscle from cerebral arteries. Data are 
means ± SEM (n=3-5). * p<0.05 compared with Normoxia. 
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APPENDIX 
 
Fig. A1. Representative tracings from normalization protocol. 
Representative original tracings showing arterial response to passive stretch during normalization 
of (A) cerebral and (B) coronary arteries. 
 
 
Fig. A2. Representative tracings for concentration response curves of bradykinin and 
acetylcholine. 
Representative original tracings of isometric tension recordings from rat isolated arteries in 
response to cumulative addition of increasing concentrations of (A) bradykinin (cerebral arteries) 
and (B) acetylcholine (coronary arteries) followed by diltiazem (10-5 M). 
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Fig. A3. Representative tracings for concentration response curves of DEA NONOate and sodium 
nitroprusside. 
Representative original tracings of isometric tension recordings from rat isolated coronary arteries 
in response to cumulative addition of increasing concentrations of (A) DEA NONOate and (B) 
sodium nitroprusside followed by diltiazem (10-5 M). 
